Naphthyridinone Derivatives for the Treatment of Diseases or Disorders - Patent application

Naphthyridinone compounds selectively inhibit GIRK1/4 channels to treat atrial fibrillation, addressing the limitations of existing class III antiarrhythmic drugs by targeting atrial tissue specifically, thereby reducing ventricular side effects and improving cardiac rhythm regulation.

JP2024543107AActive Publication Date: 2024-11-19NOVARTIS AG
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024529834
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-10-31
Filing Date
2022-11-21
Publication Date
2024-11-19
Estimated Expiration
2042-11-21

AI Technical Summary

Technical Problem

Existing class III antiarrhythmic drugs used to treat atrial fibrillation prolong the effective refractory period in both atrial and ventricular tissues, leading to potential ventricular arrhythmias and other adverse effects, necessitating the development of atrial-specific treatments that target GIRK1/4 channels to avoid ventricular side effects.

Method used

Development of naphthyridinone compounds that selectively inhibit GIRK1/4 channels, which are expressed primarily in atrial tissue, to regulate heart rate and prevent atrial fibrillation without affecting ventricular function.

Benefits of technology

The naphthyridinone compounds effectively treat atrial fibrillation by shortening the action potential duration and effective refractory period in the atria, reducing the risk of ventricular arrhythmias and improving cardiac function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543107000001_ABST
    Figure 2024543107000001_ABST
Patent Text Reader

Abstract

The present invention relates to a compound represented by formula (I) [Formula 1] TIFF2024543107000092.tif57170 (wherein A, R1 and R3 are as described herein). or a pharma- ceutically acceptable salt thereof, as well as compositions and methods of using such compounds.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to naphthyridinone compounds, their use to inhibit GIRK1 / 4 channels and methods of using same to treat diseases or disorders. [Background technology]

[0002] A normal cardiac cycle begins at the sinoatrial node, which generates an excitatory electrical impulse that propagates in an orderly fashion through the atrial and ventricular muscles to induce contraction (cardiac systole). At the cellular level, the excitatory electrical impulse induces a myocardial action potential, which is characterized by an initial rapid membrane depolarization followed by a phase of arrest and subsequent repolarization back to the resting membrane potential. The myocardial action potential controls signal propagation through the heart. For example, the rate of initial cell depolarization determines the speed at which the excitatory impulse propagates. The duration of the repolarization phase determines the action potential duration (APD) and the refractory period or the time during which the myocardial cells cannot respond to another electrical stimulus.

[0003] Abnormalities in myocardial action potentials are associated with arrhythmias. For example, excessive reduction in action potential duration and associated refractory period can provide a substrate for so-called reentrant tachyarrhythmias. In this condition, instead of propagating normally, the stimulus wave returns on itself through the excitable tissue to form a reentrant circuit (Waldo et al., Lancet 341, 1189-1193). Existing class III antiarrhythmic drugs are thought to work by extending the APD and associated effective refractory period (ERP), thereby minimizing the risk of reexcitation and subsequent formation of fibrillatory reentrant circuits (Singh et al., British Journal of pharmacology 39, 675-687).

[0004] Certain class III antiarrhythmic drugs (e.g., sotalol) are used to treat atrial fibrillation (AF). AF is the most common form of sustained cardiac arrhythmia in humans and is characterized by fibrillatory contractions that impair atrial function. AF is associated with adverse cardiovascular events. In particular, the presence of AF is an independent risk factor for thromboembolic stroke, heart failure, and all-cause mortality (Estes et al., (2008). Journal of the American College of Cardiology 51, 865-884) (Fang et al., 2008. Journal of the American College of Cardiology 51, 810-815). AF can also reduce quality of life in some patients by inducing palpitations and reducing exercise tolerance (Thrall et al., 2006. The American journal of medicine 119, 448. e441-419). The goal of antiarrhythmic drug therapy for AF is to avoid these adverse effects and consequences.

[0005] A drawback of existing class III antiarrhythmic drugs is that they act to prolong the effective refractory period in both the atria and ventricles. Excessive prolongation in ventricular tissue can prolong the QTc interval and induce arrhythmias, and some drugs with this mechanism of action (e.g., dofetilide) are known to induce potentially life-threatening ventricular arrhythmias such as torsades de pointes (Redfern et al., 2003. Cardiovascular Research 58, 32-45). Thus, there is a need for novel antiarrhythmic drug treatments for AF that selectively target atrial tissue rather than ventricular tissue.

[0006] The shape and duration of cardiac action potentials are controlled at the cellular level by the action of several different transmembrane ion channels. For example, the initial depolarization phase is mediated by cardiac-specific Na v1.5 channels. Potassium channels are involved in the later stages of repolarization and therefore help regulate the overall duration of the action potential. Indeed, class III antiarrhythmic drugs that target potassium channels (e.g., dofetilide) prolong both the action potential duration and the effective refractory period. There are several different types of transmembrane potassium channels (Schmitt et al., 2014. Physiological reviews 94, 609-653; Tamargo et al., 2004. Cardiovascular research 62, 9-33), which are Voltage-dependent channels (Kv1-9) Calcium-activated channels (KCa1-2) Tandem pore domain channels (e.g., TASK) Inward rectifier channels (Kir1-6) Includes.

[0007] While most cardiac potassium channels contribute to repolarization in both human atrial and ventricular tissues, two -K v 1.5 and GIRK1 / 4 (i.e., G protein-regulated inwardly rectifying potassium channel 1 / 4)-are thought to be expressed exclusively in the atria (Gaborit et al., 2007. The Journal of physiology 582, 675-693). This atrial-specific pattern of expression makes them particularly attractive targets for novel antiarrhythmic drug therapies for AF, since antiarrhythmic drug therapies should not have the adverse ventricular effects of existing class III drugs such as dofetilide.

[0008] Mammals express four different GIRK channels (encoded by KCNJ3, KCNJ6, KCNJ9 and KCNJ5, respectively; GIRK 1, 2, 3 and 4). These transmembrane proteins are arranged as tetramers (either homo- or heterotetramers) to form functional potassium channels (Krapivinsky et al., 1995. Nature 374, 135-141). These channels are ligand-gated (i.e., regulated by binding of ligands to Gi protein-coupled receptors present in the same cell membrane). For example, the GIRK1 / 4 channel is a heterotetramer (two subunits each of GIRK1 and GIRK4) that is strongly expressed in the sinoatrial and atrioventricular nodes and atrial muscle (Wickman et al., 1999. Annals of the New York Academy of Sciences 868, 386-398). One function of this channel is to mediate the autonomic regulation of heart rate. Acetylcholine released by parasympathetic stimulation of cardiac vagal efferent neurons binds to Gi-coupled M2 muscarinic receptors in the heart. This liberates Gβγ subunits, which in turn open GIRK1 / 4 channels to allow potassium efflux from cardiac myocytes, thereby promoting membrane repolarization. In spontaneously depolarizing pacemakers in the sinoatrial node, the extent of this repolarization determines the timing between depolarizations and therefore the heart rate. As it is regulated by acetylcholine, the current mediated by the GIRK1 / 4 channel is I KAch This is called (Wickman et al., 1999).

[0009] Several lines of evidence point to GIRK1 / 4 as a desirable antiarrhythmic target for AF. In animals, vagus nerve stimulation increases acetylcholine release from the afferent vagus nerve and I KAchThis in turn shortens the atrial (but not ventricular) action potential duration and effective refractory period, which may induce AF via a reentry mechanism (Hashimoto et al., 2006. Pharmacological research: the official journal of the Italian Pharmacological Society 54, 136-141). In atrial tissue from humans with persistent AF and from animals subjected to atrial rapid stimulation (a recognized model for promoting electrical remodeling and susceptibility to AF), I KAch It has been shown that the atrial APD / ERP is dysregulated. Specifically, the channel tends to be constitutively open even in the absence of acetylcholine (Cha et al., 2006. Circulation 113, 1730-1737; Voigt et al., 2014. Advances in pharmacology (San Diego, Calif) 70, 393-409). In these studies, shorter atrial APD / ERP is observed in patients and animals.

[0010] Therefore, the development of GIRK1 / 4 blockers would be beneficial for the treatment of various heart-related diseases. For these reasons, there remains a need for small molecule inhibitors of GIRK1 / 4. Summary of the Invention

[0011] In a first aspect, the present invention provides a compound of formula (I): [ka] (In the formula, R 1 -OH, -C(O)NHR a and a 4- to 6-membered heterocycle optionally substituted with one or more -OH (C 1 ~C 6 ) alkyl; A is -OR 2 or -SO 2 (C 1~C 4 ) alkyl, -NHC(O)R b and -C(O)NHR c (C 1 ~C 6 ) alkyl; R 2 is -NHC(O)R d and -C(O)NHR e (C 1 ~C 6 ) alkyl, (C 1 ~C 6 ) the alkyl is further optionally substituted with one or more substituents independently selected from halo, -OH and -CN; R a , R b , R c , R d and R e are each independently optionally substituted with H and one or more -OH (C 1 ~C 6 ) alkyl; and R 3 is (C 1 ~C 4 ) alkyl or a pharma- ceutically acceptable salt thereof.

[0012] In another aspect, the present invention relates to a crystalline form of a compound of formula (I) as defined herein or a pharma- ceutically acceptable salt thereof.

[0013] In another aspect, the present invention relates to a pharmaceutical composition comprising a compound of formula (I) as defined herein or a pharma- ceutically acceptable salt thereof, and one or more pharma- ceutically acceptable carriers.

[0014] In another aspect, the invention relates to a combination comprising a compound of formula (I) as defined herein, or a pharma- ceutically acceptable salt thereof, and one or more medicinal agents.

[0015] In another aspect, the present invention relates to a method for treating a disease or disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) as defined herein or a pharma- ceutically acceptable salt thereof.

[0016] In some embodiments, the disease or disorder is selected from cardiac arrhythmias, atrial fibrillation, bradyarrhythmia, bradycardia, heart block, sick sinus syndrome, parasympathetic hyperresponsiveness, primary aldosteronism, hypotension, and vasovagal syncope. In some embodiments, the disease or disorder is responsive to inhibition of the GIRK1 / 4 receptor.

[0017] In another aspect, the present invention relates to a method for treating a disease or disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) as defined herein or a pharma- ceutically acceptable salt thereof.

[0018] In yet another aspect, the invention relates to a method of maintaining sinus rhythm after cardioversion in a patient with persistent or recent onset atrial fibrillation or preventing recurrence in a patient with paroxysmal atrial fibrillation, comprising administering to a patient in need thereof a compound of formula (I) as defined herein or a pharma- ceutically acceptable salt thereof.

[0019] In another aspect, the present invention relates to a compound of formula (I) or a pharma- ceutically acceptable salt thereof as defined herein, for use as a medicament.

[0020] In another aspect, the present invention relates to a compound of formula (I) as defined herein, or a pharma- ceutically acceptable salt thereof, for use in the treatment of a disease or disorder.

[0021] In yet another aspect, the present invention relates to a compound of formula (I) as defined herein for use in the manufacture of a medicament for the treatment of a disease or disorder.

[0022] In yet another aspect, the present invention relates to the use of a compound of formula (I) as defined herein, or a pharma- ceutically acceptable salt thereof, in the treatment of a disease or disorder.

[0023] Other features and advantages of the invention will become apparent from the following detailed description and claims. [Brief description of the drawings]

[0024] [Figure A1-1] 1 shows the X-ray powder diffraction pattern of modification A-1 of Example 1. [Figure A1-2] 1 shows a differential scanning calorimetry thermogram of modification A-1 of Example 1. [Figure A1-3] 1 shows the thermogravimetric analysis of modification A-1 of Example 1. [Figure A2-1] 1 shows the X-ray powder diffraction pattern of modification A-2 of Example 1. [Figure A2-2] 1 shows a differential scanning calorimetry thermogram of modification A-2 of Example 1. [Figure A2-3] 2 shows the thermogravimetric analysis of modification A-2 of Example 1. [Figure A3-1] 1 shows the X-ray powder diffraction pattern of modification A-3 of Example 1. [Figure A3-2] 1 shows a differential scanning calorimetry thermogram of modification A-3 of Example 1. [Figure A3-3] 2 shows the thermogravimetric analysis of modification A-3 of Example 1. [Figure A4-1] 1 shows the X-ray powder diffraction pattern of modification A-4 of Example 1. [Figure A4-2] 1 shows a differential scanning calorimetry thermogram of modification A-4 of Example 1. [Figure A4-3] 4 shows the thermogravimetric analysis of modification A-4 of Example 1. [Figure A5-1] 1 shows the X-ray powder diffraction pattern of modification A-5 of Example 1. [Figure A5-2] 1 shows a differential scanning calorimetry thermogram of modification A-5 of Example 1. [Figure A5-3] 4 shows the thermogravimetric analysis of modification A-5 of Example 1. [Figure A6-1]1 shows the X-ray powder diffraction pattern of modification A-6 of Example 1. [Figure A7-1] 1 shows the X-ray powder diffraction pattern of modification A-7 of Example 1. [Figure A8-1] 1 shows the X-ray powder diffraction pattern of modification A-8 of Example 1. [Figure A9-1] 1 shows the X-ray powder diffraction pattern of modification A-9 of Example 1. [Figure A9-2] 1 shows a differential scanning calorimetry thermogram of modification A-9 of Example 1. [Figure A9-3] 1 shows the thermogravimetric analysis of modification A-9 of Example 1. [Figure A10-1] 1 shows the X-ray powder diffraction pattern of modification A-10 of Example 1. [Figure A10-2] 1 shows a differential scanning calorimetry thermogram of modification A-10 of Example 1. [Figure A10-3] 1 shows the thermogravimetric analysis of modification A-10 of Example 1. [Figure A11-1] 1 shows the X-ray powder diffraction pattern of modification A-11 of Example 1. [Figure A11-2] 1 shows a differential scanning calorimetry thermogram of modification A-11 of Example 1. [Figure A11-3] 1 shows the thermogravimetric analysis of modification A-11 of Example 1. [Figure A12-1] 1 shows the X-ray powder diffraction pattern of modification A-12 of Example 1. [Figure A12-2] 1 shows a differential scanning calorimetry thermogram of modification A-12 of Example 1. [Figure A12-3] 1 shows the thermogravimetric analysis of modification A-12 of Example 1. [Figure A13-1] 1 shows the X-ray powder diffraction pattern of modification A-13 of Example 1. [Figure A13-2] 1 shows a differential scanning calorimetry thermogram of modification A-13 of Example 1. [Figure A13-3] 1 shows the thermogravimetric analysis of modification A-13 of Example 1. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0025] In certain aspects, the present invention provides substituted naphthyridinone compounds and pharmaceutical compositions thereof.In particular, such substituted compounds are useful as inhibitors of GIRK1 / 4 receptors and have good oral bioavailability, and therefore can be used to treat or prevent diseases or conditions.

[0026] Details of the present invention are described in the accompanying description below. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, exemplary methods and materials are described herein. Other features, objects, and advantages of the present invention will be apparent from the specification and claims. In this specification and the appended claims, the singular forms include the plural unless the context clearly dictates otherwise. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs. All patents and publications cited herein are incorporated by reference in their entirety.

[0027] compound Thus, in one aspect, the present invention provides a compound of formula (I): [ka] (In the formula, R 1 -OH, -C(O)NHR a and a 4- to 6-membered heterocycle optionally substituted with one or more -OH (C 1 ~C 6 ) alkyl; A is -OR 2 or -SO 2 (C 1 ~C 4 ) alkyl, -NHC(O)R b and -C(O)NHR c (C 1 ~C 6 ) alkyl; R2 is -NHC(O)R d and -C(O)NHR e (C 1 ~C 6 ) alkyl, (C 1 ~C 6 ) the alkyl is further optionally substituted with one or more substituents independently selected from halo, -OH and -CN; R a , R b , R c , R d and R e are each independently optionally substituted with H and one or more -OH (C 1 ~C 6 ) alkyl; and R 3 is (C 1 ~C 4 ) alkyl or a pharma- ceutically acceptable salt thereof.

[0028] Unless otherwise indicated, the term "compound of the invention" or "compound of the invention" refers to the compounds of formula (I) and exemplified compounds of the invention or pharma- ceutically acceptable salts thereof, as well as stereoisomers (including diastereoisomers and enantiomers), rotamers, tautomers, hydrates, solvates, polymorphs, co-crystals, and isotopically labeled compounds (including deuterium substitutions) and inherently formed moieties.

[0029] Various embodiments of the present invention are described herein. It will be recognized that features defined in each embodiment may be combined with other defined features of other embodiments to provide further embodiments.

[0030] In one embodiment, R 1 -OH, -C(O)NHR a and a 4- to 6-membered heterocycle containing at least one O optionally substituted with one or more -OH (C 1~C 6 ) alkyl. In one embodiment, R 1 -OH, -C(O)NHR a and a 4- to 6-membered heterocycle containing at least one O optionally substituted with one -OH (C 1 ~C 6 ) alkyl. In one embodiment, R 1 -OH, -C(O)NHR a and a 4-membered heterocycle containing at least one O optionally substituted with one or more -OH (C 1 ~C 6 ) alkyl. In one embodiment, R 1 -OH, -C(O)NHR a and a 4-membered heterocycle containing at least one O substituted with one -OH (C 1 ~C 6 ) alkyl.

[0031] In one embodiment, R 1 -OH, -C(O)NHCH 3 , and [ka] (C 1 ~C 6 ) alkyl. In one embodiment, R 1 -OH, -C(O)NHCH 3 , and [ka] (C 1 ~C 4 ) alkyl.

[0032] In certain embodiments, R1 teeth, [ka] In one embodiment, R 1 teeth, [ka] In one embodiment, R 1 teeth, [ka] In one embodiment, R 1 teeth, [ka] It is.

[0033] In one embodiment, R a H and (C 1 ~C 6 ) alkyl.

[0034] In one embodiment, A is -OR 2 It is.

[0035] In one embodiment, R 2 is -NHC(O)CH 3 , -C(O)NHCH 3 , -C(O)NHCH 2 CH 2 OH and -C(O)NH 2 (C 1 ~C 6 ) alkyl, (C 1 ~C 6 ) alkyl is further optionally substituted with one or more substituents independently selected from halo, -OH, and -CN. In certain embodiments, R 2 is -NHC(O)CH 3, -C(O)NHCH 3 , -C(O)NHCH 2 CH 2 OH and -C(O)NH 2 (C 1 ~C 4 ) alkyl, (C 1 ~C 4 ) alkyl is further optionally substituted with one or more substituents independently selected from halo, -OH, and -CN. In certain embodiments, R 2 is -NHC(O)CH 3 , -C(O)NHCH 3 , -C(O)NHCH 2 CH 2 OH and -C(O)NH 2 (C 1 ~C 4 ) alkyl, (C 1 ~C 4 ) alkyl is further optionally substituted with one or more substituents independently selected from halo and -OH. In certain embodiments, R 2 is -NHC(O)CH 3 , -C(O)NHCH 3 , -C(O)NHCH 2 CH 2 OH and -C(O)NH 2 (C 1 ~C 4 ) alkyl, (C 1 ~C 4 ) The alkyl is further optionally substituted with one or more substituents independently selected from fluoro and -OH.

[0036] In certain embodiments, R 2 teeth, [ka] In one embodiment, R 2 teeth, [ka] In one embodiment, R 2 teeth, [ka] In one embodiment, R 2 teeth, [ka] In one embodiment, R 2 teeth, [ka] is selected from.

[0037] In certain embodiments, A is -SO 2 CH 3 and -NHC(O)CH 3 (C 1 ~C 6 ) alkyl. In certain embodiments, A is -SO 2 CH 3 and -NHC(O)CH 3 (C 1 ~C 4 ) alkyl.

[0038] In certain embodiments, A is [ka] In certain embodiments, A is selected from: [ka] In certain embodiments, A is selected from: [ka] It is.

[0039] In one embodiment, R 3 is -CH 3 and -CH 2 CH 3 In one embodiment, R 3 is -CH 3 It is.

[0040] In one embodiment, R a is H and (C 1 ~C 6 ) alkyl. In one embodiment, R b is H and (C 1 ~C 6 ) alkyl. In one embodiment, R c is H and (C 1 ~C 6 ) alkyl. In one embodiment, R d is H and (C 1 ~C 6 ) alkyl. In one embodiment, R 3 H and (C 1 ~C 6 ) alkyl. In one embodiment, R a is H and (C 1 ~C 4 ) alkyl. In one embodiment, R b is H and (C 1 ~C 4 ) alkyl. In one embodiment, R c is H and (C 1 ~C 4 ) alkyl. In one embodiment, R d H and (C 1 ~C 4 ) alkyl. In one embodiment, R 3 is H and (C 1 ~C 4) alkyl. In one embodiment, R e is optionally substituted with H and one or more -OH (C 1 ~C 4 ) alkyl.

[0041] In certain embodiments, the compound of formula (I) according to the present invention is a compound selected from the group consisting of:

[0042] [Table 1]

[0043] [Table 2]

[0044] [Table 3]

[0045] [Table 4]

[0046] [Table 5]

[0047] [Table 6]

[0048] [Table 7]

[0049] As used herein, the term "salt" or "salts" refers to an acid addition salt or a base addition salt of a compound of the present invention. "Salt" specifically includes "pharmaceutically acceptable salts". The term "pharmaceutically acceptable salts" refers to salts that retain the biological effectiveness and properties of the compound of the present invention and are typically not biologically or otherwise undesirable. In many cases, the compounds of the present invention can form acid salts and / or base salts due to the presence of amino and / or carboxyl groups or groups similar thereto. When both basic and acidic groups are present in the same molecule, the compounds of the present invention can also form internal salts, such as zwitterionic molecules.

[0050] Pharmaceutically acceptable acid addition salts can be formed with inorganic and organic acids.

[0051] Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.

[0052] Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and the like.

[0053] Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.

[0054] Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I-XII of the periodic table. In particular embodiments, salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include the ammonium, potassium, sodium, calcium, and magnesium salts.

[0055] Organic bases from which salts can be derived include, for example, primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, etc. Particular organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine.

[0056] In another aspect, the present invention provides an agonist, an anti-inflammatory agent ... In one embodiment, the compounds of the present invention are provided in the form of a dimethylsulfate, malate, maleate, malonate, mandelate, mesylate, methylsulfate, mucate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate / hydrogen phosphate / dihydrogen phosphate, polygalacturonate, propionate, sebacate, stearate, succinate, sulfosalicylate, sulfate, tartrate, tosylate, triphenylacetate, trifluoroacetate or xinafoate salt.

[0057] Any formula provided herein is intended to represent the unlabeled form of the compound as well as the isotopically labeled form.Isotopically labeled compounds have the structure represented by the formula provided herein, except that one or more atoms are replaced with the atom having selected atomic mass or mass number.The isotope that can be incorporated in the compound of the present invention includes, for example, hydrogen isotope.

[0058] In addition, certain isotopes, especially deuterium (i.e. 2Incorporation of H or D) may result in certain therapeutic advantages resulting from greater metabolic stability, such as increased in vivo half-life or reduced dose requirements, or improved therapeutic index or tolerability. It is understood that deuterium in this context is considered a substituent of the compounds of the present invention. The concentration of deuterium can be defined by the isotopic enrichment factor. The term "isotopic enrichment factor" as used herein means the ratio between the isotopic abundance and the natural abundance of a particular isotope. When a substituent of a compound of the present invention is designated as deuterium, such compounds have an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation). It should be understood that the term "isotopic enrichment factor" can be applied to any isotope in the same manner as described for deuterium.

[0059] Other examples of isotopes that may be incorporated into the compounds of the invention include 3 H, 11 C. 13 C. 14 C. 15 N, 18 F, 31 P, 32 P, 35 S, 36 Cl, 123 I, 124 I, 125 and isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as I. Thus, the present invention relates to, for example, 3 H and 14 Radioisotopes such as C or 2 H and 13It should be understood that compounds incorporating one or more of any of the above isotopes are included, including those in which a non-radioactive isotope such as C is present. Such isotopically labeled compounds may be useful in metabolic studies, including drug or substrate tissue distribution assays. 14 C), reaction kinetic studies (e.g. 2 H or 3 3H), positron emission tomography (PET) or single photon emission computed tomography (SPECT), or in detection or imaging techniques, or in radiotherapy of patients. 18 F or labeled compounds may be particularly desirable for PET or SPECT studies. Isotopically labeled compounds of the present invention can generally be prepared by conventional techniques known to those skilled in the art or by methods analogous to those described in the accompanying examples and general synthetic schemes, substituting the appropriate isotopically labeled reagent in place of the previously used unlabeled reagent.

[0060] Any asymmetric atom of the compounds of the present invention (e.g., carbon, etc.) may be present in racemic or enantiomerically enriched, such as (R), (S) or (R,S) configurations. In certain embodiments, each asymmetric atom has at least 50% enantiomeric excess, at least 60% enantiomeric excess, at least 70% enantiomeric excess, at least 80% enantiomeric excess, at least 90% enantiomeric excess, at least 95% enantiomeric excess or at least 99% enantiomeric excess in the (R) or (S) configuration. Substituents of atoms with unsaturated double bonds may be present in cis-(Z) or trans-(E) form, where possible.

[0061] Thus, as used herein, the compounds of the present invention may be in the form of one of the possible stereoisomers, rotamers, atropisomers, tautomers, or mixtures thereof, for example as substantially pure geometric (cis or trans) stereoisomers, diastereomers, optical isomers (enantiomers), racemates, or mixtures thereof.

[0062] Any resulting mixture of stereoisomers can be separated on the basis of the physical chemical differences of the components into pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and / or fractional crystallization.

[0063] Any resulting racemic forms of the compounds or intermediates of the present invention can be separated into their optical antipodes by known methods, for example by separation of their diastereomeric salts obtained with optically active acids or bases and liberation of optically active acidic or basic compounds. Thus, the compounds of the present invention can be resolved into their optical antipodes using basic moieties, for example by fractional crystallization of salts formed with optically active acids, such as tartaric acid, dibenzoyltartaric acid, diacetyltartaric acid, di-O,O'-p-toluoyltartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid. Racemic compounds or racemic intermediates of the present invention can also be separated by chiral chromatography, for example by high pressure liquid chromatography (HPLC) using a chiral adsorbent.

[0064] The compounds of formula (I) of the present invention (including the free form, pharma- ceutically acceptable salts, hydrates and solvates thereof) may be isolated in one or more crystalline forms under appropriate conditions.

[0065] The term "crystalline form", as used herein, includes reference to anhydrous crystalline forms, hydrated crystalline forms, solvated crystalline forms and mixtures of crystalline forms.

[0066] In one embodiment, the crystalline form of the compound of formula (I) according to the present invention or a pharma- ceutically acceptable salt thereof is selected from the free form, a hydrate, a solvate, a polymorph, and a co-crystal thereof.

[0067] The term "free form" as used herein refers to the compound of formula (I) per se, without salt formation or association with a solvent (eg, a solvate).

[0068] The term "hydrate" as used herein refers to a crystalline form containing one or more water molecules in a three-dimensional periodic arrangement. It can include non-stoichiometric or stoichiometric hydrates, such as hemihydrates, monohydrates, dihydrates, and trihydrates.

[0069] The term "solvate" as used herein refers to a crystalline form that contains one or more solvent molecules other than water in a three-dimensional periodic arrangement. Solvates can contain either stoichiometric or non-stoichiometric amounts of the solvent molecules.

[0070] In one embodiment, the compounds of formula (I) according to the present invention or pharma- ceutically acceptable salts thereof may inherently or by design form hydrates or solvates with pharma- ceutically acceptable solvents.

[0071] The term "polymorph" as used herein refers to crystalline forms having the same chemical composition but different spatial arrangements of the molecules, atoms and / or ions that form the crystal.

[0072] In one embodiment, compounds of formula (I) according to the present invention, or pharma- ceutically acceptable salts thereof, that contain groups capable of acting as donors and / or acceptors for hydrogen bonds may be capable of forming co-crystalline forms with suitable co-crystal formers.

[0073] The terms "co-crystalline" and "co-crystal" are used interchangeably herein to mean a co-crystal comprising a compound of formula (I) as defined herein or a pharma- ceutically acceptable salt thereof and a suitable co-crystal former.

[0074] These co-crystals can be prepared from the compound of formula (I) or a pharma- ceutically acceptable salt thereof by known co-crystal formation procedures, such as, for example, by contacting the compound of formula (I) or a pharma- ceutically acceptable salt thereof with a co-crystal former under grinding, heating, co-sublimation, co-melting or crystallization conditions in solution and isolating the co-crystal thereby formed. Suitable co-crystal formers include, for example, those described in WO 2004 / 078163.

[0075] In one embodiment, the present invention relates to a free crystalline form of the compound of formula (I) as defined herein.

[0076] In another embodiment, the present invention relates to a hydrate crystalline form of the compound of formula (I) as defined herein or a pharma- ceutically acceptable salt thereof. In one aspect of this embodiment, the hydrate crystalline form of the compound of formula (I) as defined herein or a pharma- ceutically acceptable salt thereof is a hemihydrate, monohydrate, dihydrate or trihydrate crystalline form.

[0077] In one embodiment, the present invention relates to a hydrate crystalline form of the compound of formula (I) as defined herein. In one aspect of this embodiment, the hydrate crystalline form of the compound of formula (I) as defined herein is a hemihydrate, monohydrate, dihydrate or trihydrate crystalline form.

[0078] In another embodiment, the present invention relates to a solvate crystalline form of the compound of formula (I) or a pharma- ceutically acceptable salt thereof as defined herein.

[0079] In one embodiment, the present invention relates to a solvate crystalline form of the compound of formula (I) as defined herein with cyclopentanone.

[0080] In another embodiment, the present invention relates to a solvate crystalline form of the compound of formula (I) as defined herein with methanol.

[0081] In another embodiment, the present invention relates to a solvate crystalline form of the compound of formula (I) as defined herein with pyridine.

[0082] In another embodiment, the present invention relates to a co-crystal of a compound of formula (I) as defined herein or a pharma- ceutically acceptable salt thereof.

[0083] In one embodiment, the present invention relates to a co-crystal comprising a compound of formula (I) as defined herein or a pharma- ceutically acceptable salt thereof and a co-crystal former. Preferably, the co-crystal former is selected from the group consisting of phosphoric acid, benzoic acid, succinic acid, saccharin and salts thereof.

[0084] In one embodiment of the present invention, there is provided a co-crystal comprising a compound of formula (I) as defined herein, or a pharma- ceutically acceptable salt thereof, and phosphoric acid.

[0085] In another embodiment of the present invention, there is provided a co-crystal comprising a compound of formula (I) as defined herein, or a pharma-ceutically acceptable salt thereof, and benzoic acid.

[0086] In another embodiment of the present invention, there is provided a co-crystal comprising a compound of formula (I) as defined herein, or a pharma-ceutically acceptable salt thereof, and succinic acid.

[0087] In another embodiment of the present invention, there is provided a co-crystal comprising a compound of formula (I) as defined herein, or a pharma-ceutically acceptable salt thereof, and saccharin.

[0088] The molar ratio of the compound of formula (I) or a pharma- ceutically acceptable salt thereof to the co-crystal former in the co-crystal of the present invention may be stoichiometric or non-stoichiometric. For example, a suitable molar ratio of the compound of formula (I) or a pharma- ceutically acceptable salt thereof to the co-crystal former in the co-crystal of the present invention is 1:2 to 2:1, preferably 1.5:1 to 1:1.5, more preferably 1:1.1 to 1.1:1.

[0089] In one embodiment, the crystalline form of the compound of formula (I) or its pharma- ceutically acceptable salt according to the present invention is provided in substantially pure form. As used herein, "substantially pure", when used in connection with a crystalline form, means a compound having a purity of more than 90% by weight, for example more than 90, 91, 92, 93, 94, 95, 96, 97, 98 and 99% by weight, or even equal to about 100% by weight, based on the weight of the compound. The remaining material includes other forms of the compound of formula (I) and / or reaction impurities and / or process impurities resulting from its preparation. For example, the crystalline form of the compound of formula (I) or its pharma- ceutically acceptable salt according to the present invention can be considered to be substantially pure in that it has a purity of more than 90% by weight, as measured by means currently known and generally accepted in the art, and the remaining material of less than 10% by weight includes other forms of the compound of formula (I) and / or reaction impurities and / or process impurities.

[0090] A particular crystalline form of the compound of formula (I) according to the present invention or a pharma- ceutically acceptable salt thereof may be referred to as "crystalline form X", "crystal form X", "co-crystal form", "polymorphic form X", "modification X" or "H X ", where "X" is the letter assigned to the particular crystalline form. It should be understood that the designations used herein to characterize particular crystalline forms, such as "A-1," should not be construed as limiting with respect to any other material having similar or identical physical and chemical properties, and that these designations are merely identifiers that should be interpreted in accordance with the characterization information provided further herein.

[0091] In one embodiment, the present invention relates to a crystalline form of the compound of formula (I) as defined herein or a pharma- ceutically acceptable salt thereof, wherein the crystalline form is selected from the various modifications detailed herein, preferably modifications A-1, A-2, A-3, A-4, A-5, A-6, A-7, A-8, A-9, A-10, A-11, A-12 and A-13.

[0092] Each modification is characterized by its X-ray powder diffraction pattern having peaks essentially as depicted in the figures. Thus, there is provided a crystalline form selected from the various modifications detailed herein, characterized in that it has an X-ray powder diffraction pattern substantially in accordance with that shown in the corresponding figure.

[0093] In a further embodiment, the present invention provides a method for the preparation of ... cellular membrane comprising the steps of: (a) an X-ray powder diffraction pattern substantially in accordance with that shown in the Figures relating to that particular modification; and / or (b) the melting points given for each modification in the Examples section; and / or (c) Differential scanning calorimetry thermograms shown for each transformation in the Examples section. The present invention provides any of the crystalline forms of the compound of formula (I) or a pharma- ceutically acceptable salt thereof described in the Examples in the form of a particular modification, characterized in that it has at least one of the following:

[0094] In one embodiment of the present invention, there is provided a free crystalline form of 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide (compound C-1), designated modification A-1, characterized in that it has an X-ray powder diffraction pattern substantially in accordance with that shown in Figure A1-1 or contains four or more 2θ values ​​(±0.1°) selected from the 2θ values ​​shown in the following table when measured at a temperature of about 22° C. using CuKα radiation having a wavelength of 1.5418 Å.

[0095] [Table 8]

[0096] In another embodiment of the present invention, there is provided a hydrate crystalline form of 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide (Compound C-1) designated modification A-2, characterized in that it has an X-ray powder diffraction pattern substantially in accordance with that shown in Figure A2-1 or contains four or more 2θ values ​​(±0.1°) selected from the 2θ values ​​shown in the following table when measured at a temperature of about 22° C. using CuKα radiation having a wavelength of 1.5418 Å.

[0097] [Table 9]

[0098] In another embodiment of the present invention, there is provided a hydrate crystalline form of 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide (Compound C-1), designated modification A-3, characterized in having an X-ray powder diffraction pattern substantially in accordance with that shown in Figure A3-1 or comprising four or more 2θ values ​​(±0.1°) selected from the 2θ values ​​shown in the following table when measured at a temperature of about 22° C. using CuKα radiation having a wavelength of 1.5418 Å:

[0099] [Table 10]

[0100] In another embodiment of the present invention, there is provided a hydrate crystalline form of 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide (Compound C-1) designated modification A-4, characterized in that it has an X-ray powder diffraction pattern substantially in accordance with that shown in Figure A4-1 or contains four or more 2θ values ​​(±0.1°) selected from the 2θ values ​​shown in the following table when measured at a temperature of about 22° C. using CuKα radiation having a wavelength of 1.5418 Å.

[0101] [Table 11]

[0102] In another embodiment of the present invention, there is provided a hydrate crystalline form of 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide (Compound C-1) designated modification A-5, characterized in that it has an X-ray powder diffraction pattern substantially in accordance with that shown in Figure A5-1 or contains four or more 2θ values ​​(±0.1°) selected from the 2θ values ​​shown in the following table when measured at a temperature of about 22° C. using CuKα radiation having a wavelength of 1.5418 Å.

[0103] [Table 12]

[0104] Pharmaceutical Compositions In another aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention or a pharma- ceutically acceptable salt thereof and one or more pharma- ceutically acceptable carriers, hi a further embodiment, the composition comprises at least two pharma- ceutically acceptable carriers, such as those described herein.

[0105] In certain embodiments, the pharmaceutical composition further comprises at least one additional pharma- ceutical active agent.In certain embodiments, the further pharma- ceutically active agent is selected from the group consisting of class I antiarrhythmic agents, class II antiarrhythmic agents, class III antiarrhythmic agents, class IV antiarrhythmic agents, class V antiarrhythmic agents, cardiac glycosides and other drugs acting on the atrial refractory period; hemostatic regulators, antithrombotic agents; thrombin inhibitors; factor VIla inhibitors; anticoagulants, factor Xa inhibitors and direct thrombin inhibitors; antiplatelet agents, cyclooxygenase inhibitors, adenosine diphosphate (ADP) receptor inhibitors, phosphodiesterase inhibitors, glycoprotein IIB / IIA, adenosine reuptake inhibitors; antidyslipidemic agents, HM G-CoA reductase inhibitors and other cholesterol-lowering agents;bile acid sequestrants;cholesterol absorption inhibitors;cholesteryl ester transfer protein (CETP) inhibitors;inhibitors of the ileal bile acid transport system (IBAT inhibitors);bile acid-binding resins;nicotinic acid and its analogues;antioxidants;omega-3 fatty acids;antihypertensives including adrenergic receptor antagonists, beta-blockers, alpha-blockers, and mixed alpha / beta-blockers;adrenergic receptor agonists, alpha-2 agonists;angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers;angiotensin II receptor antagonists;aldosterone receptor antagonists anti-obesity agents; central adrenergic agonists, central alpha agonists; and diuretics; anti-obesity agents, pancreatic lipase inhibitors, microsomal transfer protein (MTP) modulators, diacylglycerol acyltransferase (DGAT) inhibitors, cannabinoid (CBI) receptor antagonists; insulin and insulin analogues; insulin secretagogues; agents that enhance incretin action, dipeptidyl peptidase IV (DPP-4) inhibitors, glucagon-like peptide-I (GLP-1) agonists; insulin sensitizers, peroxisome proliferator-activated receptor gamma (PPARγ) agonists, hepatic agents that regulate pancreatic glucose balance, fructose 1,6-bisphosphatase inhibitors, glycogen phosphorylase inhibitors, glycogen synthase kinase inhibitors, glucokinase activators; agents designed to reduce / delay absorption of glucose from the intestine, α-glucosidase inhibitors; agents that antagonize the action of glucagon or reduce glucagon secretion, amylin analogs; agents that prevent glucose reabsorption by the kidneys and sodium-dependent glucose transporter 2 (SGLT-2) inhibitors, and combinations thereof.

[0106] Pharmaceutical compositions may be formulated for specific routes of administration, such as oral administration, parenteral administration (e.g., by injection, infusion, transdermal or topical administration) and rectal administration. Topical administration may also involve inhalation or intranasal application. Pharmaceutical compositions of the present invention may be configured in solid form (including but not limited to capsules, tablets, pills, granules, powders or suppositories) or liquid form (including but not limited to solutions, suspensions or emulsions). Tablets may be either film coated or enteric coated according to methods known in the art. Typically, pharmaceutical compositions are tablets or gelatin capsules that contain the active ingredient in combination with one or more of the following: a) diluents such as, for example, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and / or glycine; b) lubricants such as, for example, silica, talc, stearic acid, its magnesium or calcium salts and / or polyethylene glycol; Tablets also include: c) binders, such as, for example, magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and / or polyvinylpyrrolidone; if desired d) disintegrants, such as, for example, starch, agar, alginic acid or its sodium salts or effervescent mixtures; and e) Absorbents, colouring agents, flavouring agents and sweetening agents.

[0107] Liquids, particularly injectable compositions, can be prepared, for example, by dissolving, dispersing, etc. For example, the disclosed compounds are dissolved or mixed with a pharma- ceutically acceptable solvent, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, etc., to form an injectable isotonic solution or suspension. Proteins, such as albumin, chylomicron particles, or serum proteins, can be used to solubilize the disclosed compounds.

[0108] The disclosed compounds may also be formulated as suppositories which may be prepared from fatty emulsions or suspensions using polyalkylene glycols, such as propylene glycol, as the carrier.

[0109] Parenteral injectable administration is generally used for subcutaneous, intramuscular or intravenous injection and infusion. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, or solid forms suitable for dissolving in liquid prior to injection.

[0110] The compositions can be prepared according to conventional mixing, granulating or coating methods, respectively, and the pharmaceutical compositions of the present invention can contain about 0.1% to about 99%, about 5% to about 90%, or about 1% to about 20% of the disclosed compound by weight or volume.

[0111] Dosing regimens using the disclosed compounds are selected depending on a variety of factors, including the type, species, age, weight, sex, and condition of the patient; the severity of the condition being treated; the route of administration; the renal or hepatic function of the patient; and the particular disclosed compound being used. A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the drug required to prevent, combat, or arrest the progress of the condition.

[0112] The pharmaceutical composition or combination of the present invention may be, for example, a unit dose of about 1-1000 mg of active ingredient for a subject of about 50-70 kg. In one embodiment, the composition is in the form of a tablet that can be divided. The therapeutically effective dose of the compound, pharmaceutical composition or combination thereof depends on the subject's species, weight, age and individual condition, disorder or disease being treated or its severity.

[0113] How to use In yet another aspect, the present invention relates to a method for treating or preventing a disease or disorder, comprising administering to a patient in need thereof an effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt thereof or a pharmaceutical composition comprising a compound of formula (I) or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable carrier.

[0114] In another aspect, the present invention relates to a method of treating a disease or disorder comprising administering to a patient in need thereof an effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt thereof or a pharmaceutical composition comprising a compound of formula (I) or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable carrier, wherein the disease or disorder is selected from cardiac arrhythmias, atrial fibrillation, bradyarrhythmia, bradycardia, heart block, sick sinus syndrome, parasympathetic overreaction, primary aldosteronism, hypotension and vasovagal syncope.

[0115] In another aspect, the invention relates to a method of maintaining sinus rhythm after cardioversion in a patient with persistent or recent episode of atrial fibrillation or preventing recurrence in a patient with paroxysmal atrial fibrillation, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt thereof or a pharmaceutical composition comprising a compound of formula (I) or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable carrier.

[0116] In another aspect, the present invention relates to a compound of formula (I) or a pharma- ceutically acceptable salt thereof for use as a medicament.

[0117] Another aspect of the present invention relates to a compound of formula (I) or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I) or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier, for use in the treatment of a disease or disorder responsive to inhibition of the GIRK1 / 4 receptor.

[0118] In another aspect, the invention relates to a compound of formula (I) or a pharma- ceutically acceptable salt thereof or a pharmaceutical composition comprising a compound of formula (I) or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable carrier for use in the treatment, prevention, inhibition or elimination of a disease or disorder, wherein the disease or disorder is selected from cardiac arrhythmia, atrial fibrillation, bradyarrhythmia, bradycardia, heart block, sick sinus syndrome, parasympathetic hyperresponsiveness, primary aldosteronism, hypotension and vasovagal syncope.

[0119] In another aspect, the invention relates to a compound of formula (I) or a pharma- ceutically acceptable salt thereof or a pharmaceutical composition comprising a compound of formula (I) or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable carrier for use in maintaining sinus rhythm after cardioversion in patients with persistent or recent onset atrial fibrillation or in preventing recurrence in patients with paroxysmal atrial fibrillation.

[0120] Another aspect of the present invention relates to the use of a compound of formula (I) or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I) or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier, in the manufacture of a medicament for the treatment of a disease or disorder responsive to inhibition of the GIRK1 / 4 receptor.

[0121] In another aspect, the invention relates to the use of a compound of formula (I) or a pharma- ceutically acceptable salt thereof or a pharmaceutical composition comprising a compound of formula (I) or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable carrier, in the treatment of a disease or disorder, wherein the disease or disorder is selected from cardiac arrhythmia, atrial fibrillation, bradyarrhythmia, bradycardia, heart block, sick sinus syndrome, parasympathetic hyperresponsiveness, primary aldosteronism, hypotension and vasovagal syncope.

[0122] In another aspect, the invention relates to the use of a compound of formula (I) or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I) or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable carrier, in maintaining sinus rhythm after cardioversion in patients with persistent or recent onset atrial fibrillation or preventing recurrence in patients with paroxysmal atrial fibrillation.

[0123] In certain embodiments, the disease or disorder is a disease or disorder responsive to inhibition of the GIRK1 / 4 receptor. In some embodiments, the disease or disorder responsive to inhibition of the GIRK1 / 4 receptor is selected from cardiac arrhythmia, atrial fibrillation, bradyarrhythmia, bradycardia, heart block, sick sinus syndrome, parasympathetic hyperresponsiveness, primary aldosteronism, hypotension, and vasovagal syncope.

[0124] In certain embodiments, the disease or disorder is selected from cardiac arrhythmias, atrial fibrillation, bradyarrhythmia, bradycardia, heart block, sick sinus syndrome, parasympathetic hyperresponsiveness, primary aldosteronism, hypotension, and vasovagal syncope.

[0125] The disclosed compounds of the present invention can be administered in an effective amount to treat or prevent a disorder and / or prevent its onset in a subject.

[0126] In certain embodiments, administration of the compound is oral.

[0127] Combination therapy The compounds of the present invention can be administered in a therapeutically effective amount in combination therapy with one or more pharmacologic active agents (pharmaceutical combinations) or therapies, such as non-pharmacologic therapies.For example, synergistic effects can occur with other cardiovascular agents, antihypertensives, coronary dilators and diuretics.When the compounds of the present application are administered together with other therapies, the dosage of the co-administered compound will of course vary depending on the type of co-drug used, the specific drug used, the pathology being treated, etc.

[0128] The compounds of the present invention can be administered simultaneously with, before or after one or more other pharma- ceutically active agents.The compounds of the present invention can be administered separately, by the same or different administration route, or together with other agents in the same pharmaceutical composition.The pharma-ceutically active agent can be, for example, a chemical compound, a peptide, an antibody, an antibody fragment, or a nucleic acid, which has therapeutic activity or enhances therapeutic activity when administered to a patient in combination with the compounds of the present invention.

[0129] In one embodiment, the present invention provides a product comprising the compound of the present invention and at least one other pharma- ceutical active agent as a combined preparation for simultaneous, separate or sequential use in treatment. In one embodiment, the treatment is the treatment of a disease or disorder that responds to the inhibition of GIRK1 / 4 receptor. The product provided as a combined preparation includes a composition that comprises the compound of the present invention and the other pharma- ceutical active agent together in the same pharmaceutical composition as described herein, or in separate forms, for example in the form of a kit.

[0130] In another aspect, the invention includes a compound of formula (I) or a pharma- ceutically acceptable salt thereof for use in combination therapy.

[0131] Another aspect of the present invention relates to a pharmaceutical composition comprising a compound of formula (I) or a pharma- ceutically acceptable salt thereof, a pharma- ceutically acceptable carrier and one or more pharma- ceutical active agents. The pharma- ceutically acceptable carrier may further comprise an excipient, diluent or surfactant.

[0132] Combination therapy includes administration of the compound of the present invention further combined with other biologically active ingredients.For example, the compound of the present application can be used in combination with other pharma- ceutical active agents, preferably compounds that can enhance the effect of the compound of the present application.The compound of the present application can be administered simultaneously (as a single formulation or separate formulations) or sequentially with other drug therapies or treatments.Generally, combination therapy contemplates administration of two or more drugs during a single treatment cycle or course of treatment.

[0133] Exemplary additional pharma- ceutically active agents that may be used in combination with the compounds of the invention include, but are not limited to, any other antiarrhythmic agent, such as Class I antiarrhythmic agents (e.g., quinidine, lidocaine, and propafenone), Class II antiarrhythmic agents (e.g., propranolol), Class III antiarrhythmic agents (e.g., sotalol, dofetilide, amiodarone, dronedarone, budiodarone, azimilide, and ibutilide), Class IV antiarrhythmic agents (e.g., diltiazem and verapamil), Class V antiarrhythmic agents (e.g., adenosine), cardiac glycosides (e.g., digitalis and ouabain), and other drugs acting on the atrial refractory period (e.g., Class I antiarrhythmic agents, such as those described in WO 2013 / 112932). Na,Lateblockers); hemostatic regulators, including antithrombotic agents such as activators of fibrinolysis; thrombin inhibitors; factor VIla inhibitors; anticoagulants, such as vitamin K antagonists (e.g., warfarin), heparin and its low molecular weight analogues (e.g., dalteparin), factor Xa inhibitors (e.g., rivaroxaban and apixaban) and direct thrombin inhibitors (e.g., argatroban); antiplatelet agents, such as cyclooxygenase inhibitors (e.g., aspirin and NSAIDs), adenosine diphosphate (ADP) receptor inhibitors antihyperlipidemic agents, such as HMG-CoA reductase inhibitors (statins) and other cholesterol-lowering agents; PPARα agonists (fibrates, such as gemfibrozil and fenofibrate); bile acid sequestrants (e.g. cholestyramine); cholesterol absorption inhibitors (e.g. endothelial growth factor receptor agonists); monosterols (i.e., phytosterols), synthesis inhibitors; cholesteryl ester transfer protein (CETP) inhibitors; inhibitors of the ileal bile acid transport system (IBAT inhibitors); bile acid-binding resins; nicotinic acid (niacin) and its analogs; antioxidants; and omega-3 fatty acids; adrenergic receptor antagonists, such as antihypertensives, including beta-blockers (e.g., atenolol), alpha-blockers (e.g., doxazosin), and mixed alpha / beta-blockers (e.g., labetalol); adrenergic receptor antagonists, including alpha-2 agonists (e.g., clonidine). systemic agonists; angiotensin-converting enzyme (ACE) inhibitors (e.g., lisinopril), calcium channel blockers, such as dihydropyridines (e.g., nifedipine), phenylalkylamines (e.g., verapamil), and benzothiazepines (e.g., diltiazem); angiotensin II receptor antagonists (e.g., losartan); aldosterone receptor antagonists (e.g., eplerenone); central adrenergic agonists, such as central alpha agonists (e.g., clonidine); and diuretics (e.g., furosemide);Antiobesity agents, such as appetite suppressants (e.g., ephedrine), including noradrenergic agonists (e.g., phentermine) and serotonergic agents (e.g., sibutramine), pancreatic lipase inhibitors (e.g., orlistat), microsomal transfer protein (MTP) modulators, diacylglycerol acyltransferase (DGAT) inhibitors, and cannabinoid (CBI) receptor antagonists (e.g., rimonabant); insulin and insulin analogues; sulfonyl Insulin secretagogues, including ureas (e.g., glipizide) and prandial glucose regulators (which may be referred to as "short-acting secretagogues"), such as the meglitinides (e.g., repaglinide and nateglinide); agents that enhance incretin action, such as dipeptidyl peptidase IV (DPP-4) inhibitors (e.g., vildagliptin, sitagliptin, LAF237, MK-431) and glucagon-like peptide-I (GLP-1) agonists (e.g., exenatidine, insulin sensitizers, including peroxisome proliferator-activated receptor gamma (PPARy) agonists, such as thiazolidinediones (e.g., pioglitazone and rosiglitazone) and agents with any combination of PPARα, γ and δ activity; agents that regulate hepatic glucose balance, such as biguanides (e.g., metformin), fructose 1,6-bisphosphatase inhibitors, glycogen phosphorylase inhibitors, glycogen synthase kinase inhibitors and glucokinase activators; agents designed to reduce / delay absorption of glucose from the intestine, such as α-glucosidase inhibitors (e.g., miglitol and acarbose); agents that antagonize the action of glucagon or reduce glucagon secretion, such as amylin analogues (e.g., pramlintide); agents that prevent glucose reabsorption by the kidney, such as sodium-dependent glucose transporter 2 (SGLT-2) inhibitors.

[0134] The term "HMG-Co-A reductase inhibitors" (also called β-hydroxy-β-methylglutaryl-co-enzyme-A reductase inhibitors) includes active agents that can be used to lower lipid levels, including cholesterol, in the blood. Examples include atorvastatin, cerivastatin, compactin, dalvastatin, dihydrocompactin, fluindostatin, fluvastatin, lovastatin, pitavastatin, mevastatin, pravastatin, rivastatin, simvastatin, and belostatin, or a pharma- ceutically acceptable salt thereof.

[0135] The term "ACE inhibitors" (also called angiotensin-converting enzyme inhibitors) includes molecules that prevent the enzymatic degradation of angiotensin I to angiotensin II. Such compounds can be used to regulate blood pressure and treat congestive heart failure. Examples include alacepril, benazepril, benazeprilat, captopril, ceronapril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, imidapril, lisinopril, moveltopril, perindopril, quinapril, ramipril, spirapril, temocapril, and trandolapril or a pharma- ceutically acceptable salt thereof.

[0136] The angiotensin II receptor antagonist or a pharma- ceutical acceptable salt thereof is an angiotensin II receptor antagonist that inhibits the AT 1 It is understood that an active ingredient binds to a receptor subtype but does not result in activation of the receptor. 1 As a result of receptor inhibition, these antagonists can be used, for example, as antihypertensive agents or to treat congestive heart failure.

[0137] The term "diuretic" includes thiazide derivatives (eg, chlorothiazide, hydrochlorothiazide, methylclothiazide, and chlorothiaridone).

[0138] DPP-IV is responsible for inactivating GLP-1. More specifically, DPP-IV generates GLP-1 receptor antagonists, thereby shortening the physiological response to GLP-1. GLP-1 is the main stimulator of pancreatic insulin secretion and has a direct beneficial effect on glucose disposal. DPP-IV inhibitors can be peptidic or preferably non-peptidic. DPP-IV inhibitors include, but are not limited to, sitagliptin, linagliptin, saxagliptin and alogliptin. DPP-IV inhibitors are also generally and specifically disclosed, for example, in WO 98 / 19998, DE 196 16 486 A1, WO 00 / 34241 and WO 95 / 15309, respectively, in particular in the compound claims and final products of the examples, and the subject matter of the final products, pharmaceutical formulations and claims are incorporated in this application by reference to these publications. Preferred are the compounds specifically disclosed in Example 3 of WO 98 / 19998 and Example 1 of WO 00 / 34241, respectively.

[0139] GLP-1 is an insulinotropic protein described, for example, in W. E. Schmidt et al., Diabetologia, 28, 1985, 704-707 and U.S. Pat. No. 5,705,483. The term "GLP-1 agonist" refers in particular to the GLP-1(7-36)NH agonist, which is disclosed in U.S. Pat. Nos. 5,120,712, 5,118,666, 5,512,549, WO 91 / 11457 and C. Orskov et al., J. Biol. Chem. 264 (1989) 12826. 2 Further examples include variants and analogs of Arg 36 The carboxy-terminal amide functional group of GLP-1(7-36)NH 2 GLP-1(7-37) and GLN, which are substituted with Gly at the 37th position of the molecule 9 -GLP-1(7-37), D-GLN 9-GLP-1(7-37), Acetyl LYS 9 -GLP-1(7-37), LYS 18 -GLP-1(7-37) and in particular GLP-1(7-37)OH, VAL 8 -GLP-1(7-37), GLY 8 -GLP-1(7-37), THR 8 -GLP-1(7-37), MET 8 -GLP-1(7-37) and variants and analogs thereof, including 4-imidazopropionyl-GLP-1.GLP-1 receptor agonists include, but are not limited to, semaglutide, exenatide and liraglutide.

[0140] It is understood that an aldosterone synthase inhibitor or its pharma- ceutically acceptable salt is an active ingredient that has the property of inhibiting the production of aldosterone.Aldosterone synthase (CYP11B2) is a mitochondrial cytochrome P450 enzyme that catalyzes the last step of aldosterone production in the adrenal cortex, namely the conversion of 11-deoxycorticosterone to aldosterone.The inhibition of aldosterone production by so-called aldosterone synthase inhibitors is known to be a successful form of treatment for hypokalemia, hypertension, congestive heart failure, atrial fibrillation or renal failure.Such aldosterone synthase inhibitory activity is easily determined by those skilled in the art according to standard assays (e.g., US Patent Publication No. 2007 / 0049616).

[0141] The class of aldosterone synthase inhibitors includes both steroidal and non-steroidal aldosterone synthase inhibitors, the latter being most preferred.

[0142] The class of aldosterone synthase inhibitors comprises compounds with different structural features, for example, compounds selected from the group consisting of the non-steroidal aromatase inhibitors anastrozole, fadrozole (including its (+)-enantiomer) and the steroidal aromatase inhibitor exemestane, or, where applicable, a pharma- ceutically acceptable salt thereof.

[0143] The most preferred non-steroidal aldosterone synthase inhibitor is the (+)-enantiomer of the hydrochloride salt of fadrozole or, where appropriate, a pharma- ceutically acceptable salt thereof.

[0144] Preferred steroidal aldosterone antagonists are eplerenone or spironolactone; or, where appropriate, a pharma- ceutically acceptable salt thereof.

[0145] Aldosterone synthase inhibitors useful in said combinations are, for example, the compounds and analogues generally and specifically disclosed in US Patent Application Publication No. 2007 / 0049616, in particular the compound claims and the final products of the Examples, the final products, pharmaceutical formulations and subject matter of the claims being incorporated into this application by reference to this publication.

[0146] The term aldosterone synthase inhibitor also includes compounds and analogues disclosed in WO 2008 / 076860, WO 2008 / 076336, WO 2008 / 076862, WO 2008 / 027284, WO 2004 / 046145, WO 2004 / 014914, WO 2001 / 076574.

[0147] Additionally, aldosterone synthase inhibitors are disclosed in U.S. Patent Application Publication No. 2007 / 0225232, U.S. Patent Application Publication No. 2007 / 0208035, U.S. Patent Application Publication No. 2008 / 0318978, U.S. Patent Application Publication No. 2008 / 0076794, U.S. Patent Application Publication No. 2009 / 0012068, U.S. Patent Application Publication No. 2009 / 0048241, and PCT Publication No. WO 2006 / 005726. , WO 2006 / 128853, WO 2006128851, WO 2006 / 128852, WO 2007 / 065942, WO 2007 / 116099, WO 2007 / 116908, WO 2008 / 119744 and European Patent Application No. 1 886 695 and also include compounds and analogues disclosed therein.

[0148] The term "CETP inhibitor" refers to compounds that inhibit the cholesteryl ester transfer protein (CETP)-mediated transport of various cholesteryl esters and triglycerides from HDL to LDL and VLDL. Such CETP inhibitory activity is readily determined by those skilled in the art according to standard assays (e.g., U.S. Pat. No. 6,140,343). Examples include compounds disclosed in U.S. Pat. Nos. 6,140,343 and 6,197,786 (e.g., [2R,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester (torcetrapib); compounds disclosed in U.S. Pat. No. 6,723,752 (e.g., (2R)-3-{[3-(4-chloro-3-ethyl-phenoxy)-phenyl]-[[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-methyl]-amino}-1,1,1-trifluoro-2-propanol); U.S. Pat. The compounds disclosed in application Ser. No. 10 / 807,838; the polypeptide derivatives disclosed in U.S. Pat. No. 5,512,548; the rosenonolactone derivatives and phosphate-containing analogs of cholesteryl esters disclosed in J. Antibiot., 49(8):815-816 (1996) and Bioorg. Med. Chem. Lett., 6:1951-1954 (1996), respectively. In addition, CETP inhibitors include those disclosed in WO 2000 / 017165, WO 2005 / 095409 and WO 2005 / 097806.

[0149] In another embodiment, the other therapeutic agent is selected from: Any other antiarrhythmic agent may be used, such as class I antiarrhythmic agents (e.g., quinidine, lidocaine and propafenone), class II antiarrhythmic agents (e.g., propranolol), class III antiarrhythmic agents (e.g., sotalol, dofetilide, amiodarone, dronedarone, budiodarone, azimilide and ibutilide), class IV antiarrhythmic agents (e.g., diltiazem and verapamil), class V antiarrhythmic agents (e.g., adenosine), cardiac glycosides (e.g., digitalis and ouabain) and other drugs acting on the atrial refractory period (e.g., class I antiarrhythmic agents such as those described in WO 2013 / 112932). Na,Late blockers).

[0150] "Combination therapy" is intended to include sequential administration of these therapeutic agents, with each therapeutic agent being administered at different times and in any order, or alternating and in any order, and with the administration of at least two of these therapeutic agents or therapeutic agents being administered substantially simultaneously. Substantially simultaneous administration can be performed, for example, by administering to the subject a single capsule having a fixed ratio of each therapeutic agent, or a single capsule multiple times for each of the therapeutic agents. Sequential or substantially simultaneous administration of each therapeutic agent can be performed by any suitable route, including, but not limited to, oral, intravenous, intramuscular, and direct absorption through mucosal tissue. The therapeutic agents can be administered by the same route or by different routes. For example, a first therapeutic agent of the selected combination can be administered by intravenous injection, while the other therapeutic agent of the combination can be administered orally. Alternatively, for example, all therapeutic agents can be administered orally, or all therapeutic agents can be administered by intravenous injection. The order in which the therapeutic agents are administered is not narrowly important.

[0151] Process for the preparation of compounds of formula (I) The compounds of formula (I) of the invention may be made by a variety of methods, including standard chemistry. Suitable synthetic routes are illustrated in the schemes set out below.

[0152] Compounds of formula (I) can be prepared by methods known in the art of organic synthesis, as illustrated in part by the following synthetic schemes. In the schemes described below, it is fully understood that protecting groups for sensitive or reactive groups are used as necessary according to general principles or chemistry. Protecting groups are manipulated according to standard methods of organic synthesis (TW Greene and PG M Huts, "Protective Groups in Organic Synthesis", Third edition, Wiley, New York 1999). These groups are removed at a convenient stage of the compound synthesis, using methods readily apparent to those skilled in the art. The selected processes and reaction conditions and the order of their execution shall be consistent with the preparation of compounds of formula (I).

[0153] Those skilled in the art will recognize whether a stereocenter exists in the compound of formula (I). Thus, the present invention includes both possible stereoisomers (unless otherwise specified in the synthesis), including not only the racemates but also the individual enantiomers and / or diastereomers. When a compound is desired as a single enantiomer or diastereomer, it can be obtained by stereospecific synthesis or by resolution of the final product or any convenient intermediate. Resolution of the final product, intermediate, or starting material can be affected by any suitable method known in the art. See, for example, "Stereochemistry of Organic Compounds" by EL Eliel, SH Wilen, and LN Mander (Wiley-Interscience, 1994).

[0154] The compounds described herein can be made from commercially available starting materials or can be synthesized using known organic, inorganic and / or enzymatic processes.

[0155] definition Terms not specifically defined herein should be given the meaning that could be given to them by one of ordinary skill in the art in view of the invention and the context. For purposes of interpreting this specification, the following definitions shall apply unless otherwise indicated and whenever appropriate, and terms used in the singular shall include the plural and vice versa.

[0156] It must be noted that, as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a "pharmaceutical formulation" includes reference to one or more pharmaceutical formulations, and so forth.

[0157] The term "acyl", as used herein, refers to a group represented by the general formula hydrocarbylC(O)-, preferably alkylC(O)-.

[0158] The term "acyloxy", as used herein, refers to a group represented by the general formula hydrocarbylC(O)O-, preferably alkylC(O)O-.

[0159] The term "alkenyl", as used herein, refers to an aliphatic group containing at least one double bond, and is intended to include both "unsubstituted alkenyl" and "substituted alkenyl", the latter of which refers to an alkenyl moiety having a substituent replacing a hydrogen on one or more carbons of the alkenyl group. Such a substituent may be present on one or more carbons that are included or not included in one or more double bonds. Furthermore, such substituents include all of those contemplated for an alkyl group, as described below, except where stability would be impaired. For example, substitution of an alkenyl group with one or more alkyl, carbocyclyl, aryl, heterocyclyl, or heteroaryl groups is contemplated. Examples of alkenyl groups include ethenyl, propenyl, n-butenyl, iso-butenyl, pentenyl, or hexenyl.

[0160] The term "alkoxy" as used herein refers to an alkyl group, preferably a lower alkyl group having an oxygen attached thereto, e.g., -O(alkyl). Representative alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, tert-butoxy, and the like. Representative substituted alkoxy groups include, but are not limited to, -OCF 3 etc.

[0161] An "alkyl" group or "alkane" is a fully saturated straight or branched chain non-aromatic hydrocarbon. Typically, a straight or branched chain alkyl group has from 1 to about 20 carbon atoms, preferably from 1 to about 10, unless otherwise defined. Examples of straight and branched chain alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, pentyl, hexyl, pentyl and octyl. 1 ~C 6 Straight chain or branched chain alkyl groups are also referred to as "lower alkyl" groups.

[0162] The term "alkynyl," as used herein, refers to an aliphatic group that contains at least one triple bond. Examples of alkynyl groups include ethynyl, propargyl, n-butynyl, iso-butynyl, pentynyl, or hexynyl.

[0163] The term "aryl" as used herein includes substituted or unsubstituted monocyclic aromatic groups in which each atom of the ring is carbon. Preferably, the ring is a 5- to 7-membered ring, more preferably a 6-membered ring. The term "aryl" also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjacent rings, at least one of the rings being aromatic, for example, the other cyclic rings may be cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl and / or heterocyclyl. Aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, anthracenyl, phenalenyl, phenanthrenyl, indanyl, indenyl, tetrahydronaphthalenyl, tetrahydrobenzoannulenyl, and the like.

[0164] "C x~y The term "C" when used with a chemical moiety such as acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy is meant to include groups containing x to y carbons in the chain. For example, "C x~y The term "alkyl" refers to substituted or unsubstituted saturated hydrocarbon groups, including straight-chain alkyl and branched-chain alkyl groups containing x to y carbons in the chain, including haloalkyl groups such as trifluoromethyl and 2,2,2-trifluoroethyl. 0 Alkyl denotes hydrogen when the group is in a terminal position and a bond when the group is in an internal position. 2~y alkenyl" and "C 2~y The term "alkynyl" refers to substituted or unsubstituted unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described herein, but which contain at least one double or triple bond respectively.

[0165] The terms "carbocycle" and "carbocyclic", as used herein, refer to a saturated or unsaturated ring in which each atom of the ring is carbon. The term carbocycle includes both aromatic and non-aromatic carbocycles. Non-aromatic carbocycles include both cycloalkane rings in which all carbon atoms are saturated and cycloalkene rings that contain at least one double bond. "Carbocycle" includes 5-7 membered monocyclic and 8-12 membered bicyclic rings. Each ring of a bicyclic carbocycle may be selected from saturated, unsaturated, and aromatic rings. Carbocycles include bicyclic molecules in which one, two, or three or more atoms are shared between the two rings. The term "fused carbocycle" refers to a bicyclic carbocycle in which each of the rings shares two adjacent atoms with the other ring. Each ring of a fused carbocycle may be selected from saturated, unsaturated, and aromatic rings. In an exemplary embodiment, an aromatic ring, such as phenyl, may be fused to a saturated or unsaturated ring, such as cyclohexane, cyclopentane, or cyclohexene. Any combination of saturated, unsaturated and aromatic bicyclic rings is included in the definition of carbocycle, as valence permits. Exemplary "carbocycles" include cyclopentane, cyclohexane, bicyclo[2.2.1]heptane, 1,5-cyclooctadiene, 1,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]oct-3-ene, naphthalene and adamantane. Exemplary fused carbocycles include decalin, naphthalene, 1,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]octane, 4,5,6,7-tetrahydro-1H-indene and bicyclo[4.1.0]hept-3-ene. A "carbocycle" may be substituted at any one or more positions capable of carrying a hydrogen atom.

[0166] A "cycloalkyl" group is a fully saturated cyclic hydrocarbon. "Cycloalkyl" includes monocyclic and bicyclic rings. Typically, a monocyclic cycloalkyl group has 3 to about 10 carbon atoms, more typically 3 to 8 carbon atoms, unless otherwise defined. The second ring of a bicyclic cycloalkyl may be selected from saturated, unsaturated, and aromatic rings. Cycloalkyl includes bicyclic molecules in which one, two, or three or more atoms are shared between the two rings. The term "fused cycloalkyl" refers to a bicyclic cycloalkyl in which each of the rings shares two adjacent atoms with the other ring. The second ring of a fused bicyclic cycloalkyl may be selected from saturated, unsaturated, and aromatic rings.

[0167] The terms "halo" and "halogen" as used herein mean halogen and include chloro, fluoro, bromo and iodo.

[0168] The terms "hetarylalkyl" and "heteroarylalkyl," as used herein, refer to an alkyl group substituted with a hetaryl group.

[0169] The term "heteroalkyl," as used herein, refers to a saturated or unsaturated chain of carbon atoms and at least one heteroatom, where no two heteroatoms are adjacent.

[0170] The terms "heteroaryl" and "hetaryl" include substituted or unsubstituted aromatic monocyclic ring structures, preferably 5- to 7-membered rings, more preferably 5- to 6-membered rings, whose ring structures contain at least one heteroatom, preferably 1 to 4 heteroatoms, more preferably 1 or 2 heteroatoms. The terms "heteroaryl" and "hetaryl" also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjacent rings, and at least one of the rings is heteroaromatic, e.g., the other cyclic rings can be cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, and / or heterocyclyl. Heteroaryl groups include, but are not limited to, furyl, thienyl, pyrrolyl, pyridyl, pyridyl N-oxide, pyrazolyl, pyrimidinyl, imidazolyl, isoxazolyl, oxazolyl, oxadiazolyl, pyrazinyl, indolyl, thiophen-2-yl, quinolyl, benzopyranyl, isothiazolyl, thiazolyl, thiadiazole, indazole, benzimidazolyl, thieno[3,2 -b]thiophene, triazolyl, triazinyl, imidazo[1,2-b]pyrazolyl, furo[2,3-c]pyridinyl, imidazo[1,2-a]pyridinyl, indazolyl, pyrrolo[2,3-c]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrazolo[3,4-c]pyridinyl, thieno[3,2-c]pyridinyl, thieno[2,3-c]pyridinyl, thieno[2,3-b]pyridinyl, ben Zothiazolyl, indolyl, indolinyl, indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, benzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, dihydrobenzoxanyl, quinolinyl, isoquinolinyl, 1,6-naphthyridinyl, benzo[de]isoquinolinyl, pyrido[4,3-b][1, 6]naphthyridinyl, thieno[2,3-b]pyrazinyl, quinazolinyl, tetrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, isoindolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,4-b]pyridinyl, pyrrolo[3,2-b]pyridinyl, imidazo[5,4-b]pyridinyl, pyrrolo[1,2-a]pyrimidinyl, tetrahydropyrrolo[1,2-a]pyrimidinyl, 3,4-dihydro-2H-1Δ2-pyrrolo[2,1-b]pyrimidine, dibenzo[b,d]thiophene, pyridin-2-one, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, 1H-pyrido[3,4-b][1,4]thiazinyl, benzoxazolyl, benzisoxazolyl, furo[2,3-b]pyridinyl, benzothiophenyl, 1,5-naphthyridinyl, furo[3,2-b]pyridine, [1,2,4]triazolo[l,5-a] Pyridinyl, benzo[1,2,3]triazolyl, imidazo[1,2-a]pyrimidinyl, [1,2,4]triazolo[4,3-b]pyridazinyl, benzo[c][1,2,5]thiadiazolyl, benzo[c][1,2,5]oxadiazole, 1,3-dihydro-2H-benzo[d]imidazol-2-one, 3,4-dihydro-2H-pyrazolo[1,5-b][1,2]oxazinyl, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridinyl, thiazolo[5,4 d]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, thieno[2,3-b]pyrrolyl, 3H-indolyl, indolinyl, indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, 3,4-dihydro-1H-isoquinolinyl, 2,3-dihydrobenzofuran, indolinyl, indolyl and dihydrobenzoxanyl.

[0171] The term "heteroatom" as used herein means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen and sulfur.

[0172] The terms "heterocyclyl", "heterocycle" and "heterocyclic" refer to a substituted or unsubstituted non-aromatic ring structure, preferably a 3- to 10-membered ring, more preferably a 3- to 7-membered ring, whose ring structure contains at least one heteroatom, preferably 1 to 4 heteroatoms, more preferably 1 or 2 heteroatoms. The terms "heterocyclyl" and "heterocyclic" also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjacent rings, where at least one of the rings is heterocyclic, for example, the other cyclic rings can be cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl and / or heterocyclyl. Heterocyclyl groups include, for example, piperidine, piperazine, pyrrolidine, morpholine, lactones, lactams, and the like. Heterocyclyl groups can also be substituted with oxo groups. For example, "heterocyclyl" encompasses both pyrrolidine and pyrrolidinone.

[0173] "Haloalkyl," as used herein, refers to an alkyl group that is substituted with one or more halogens. Examples of haloalkyl groups include, but are not limited to, trifluoromethyl, difluoromethyl, pentafluoroethyl, trichloromethyl, and the like.

[0174] As used herein, the term "oxo" refers to a carbonyl group. When an oxo substituent is present on an otherwise saturated group, such as in the case of an oxo-substituted cycloalkyl group (e.g., 3-oxo-cyclobutyl), the substituted group is still intended to be saturated. When a group is referred to as being substituted with an "oxo" group, this means that the carbonyl moiety (i.e., -C(=O)-) has been replaced with a methylene unit (i.e., -CH 2 -) can be meant to replace

[0175] The term "optionally substituted" means that a given chemical moiety (e.g., an alkyl group) can be (but need not be) attached to another substituent (e.g., a heteroatom). For example, an optionally substituted alkyl group can be a fully saturated alkyl chain (e.g., a pure hydrocarbon). Alternatively, the same optionally substituted alkyl group can have substituents other than hydrogen, where the substituents are as defined herein. "Optionally substituted," as used herein, can also refer to substituted or unsubstituted, the meanings of which are described below.

[0176] The term "substituted" means that the specified group or moiety bears one or more suitable substituents, and the substituents may be linked to the specified group or moiety at one or more positions. For example, an aryl substituted with a cycloalkyl may indicate that the cycloalkyl is linked to an atom of the aryl by a bond or by being fused with the aryl, sharing two or more common atoms.

[0177] The term "unsubstituted" means that the specified group bears no substituents.

[0178] A "patient" or "subject" is a mammal, such as a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or a non-human primate, such as a monkey, chimpanzee, baboon, or rhesus monkey. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is a human.

[0179] The term "pharmacologically effective amount" or "therapeutically effective amount" or "effective amount" refers to an amount of a compound of the present invention that, when administered to a patient in need thereof, is sufficient to effect treatment of a disease state, condition, or disorder for which the compound has utility. Such an amount will be sufficient to elicit the biological or medical response of a tissue, system, or patient that is desired by the researcher or clinician. The amount of a compound of the present invention that constitutes a therapeutically effective amount will vary depending on factors such as the compound and its biological activity, the composition used for administration, the time of administration of the compound, the route of administration, the rate of excretion, the duration of treatment, the type and severity of the disease state or disorder being treated, drugs used in combination or simultaneously with the compound of the present invention, and the patient's age, weight, general health, sex, and dietary habits. Such a therapeutically effective amount can be routinely determined by one of ordinary skill in the art having regard to their own knowledge, the prior art, and this invention.

[0180] As used herein, the term "pharmaceutical composition" refers to a compound of the present invention or a pharma- ceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, together with at least one pharma- ceutically acceptable carrier, in a form suitable for oral or parenteral administration.

[0181] "Carrier" includes carriers, excipients and diluents and means a material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, that is involved in carrying or transporting a pharmaceutical agent from one organ or part of the body to another organ or part of the body of a subject.

[0182] "Combination" refers to either a fixed combination in one unit dosage form or a combined administration in which the compound of the present invention and at least one combination partner (e.g., another drug, also referred to as "therapeutic agent" or "co-drug", as described below) can be administered independently, simultaneously or separately within a time interval, in particular, where these time intervals allow the combination partners to exhibit a beneficial effect due to the interaction of these therapeutic agents. The beneficial effect of the combination includes, but is not limited to, a synergistic effect, such as a synergistic effect and / or a pharmacokinetic or pharmacodynamic interaction, or any combination thereof, resulting from the combination of therapeutic agents. In one embodiment, the administration of these therapeutic agents in the combination is performed over a defined period of time (e.g., minutes, hours, days, or weeks, depending on the combination selected).

[0183] A single component can be packaged in a kit or separately. One or both of the components (e.g., powder or liquid) can be reconstituted and diluted to a desired dose before administration. Terms such as "co-administration" or "combined administration" as used herein are intended to encompass the administration of selected combination partners to a single subject (e.g., patient) in need thereof, and are intended to include therapeutic regimens in which agents are not necessarily administered by the same route of administration or at the same time.

[0184] The term "pharmaceutical combination", as used herein, refers to the product resulting from mixing or combining two or more therapeutic agents, and includes both fixed and non-fixed combinations of therapeutic agents. The term "fixed combination" means that both therapeutic agents, e.g., a compound of the present invention and a combination partner, are administered to a patient simultaneously in the form of a single entity or dosage. The term "non-fixed combination" means that both therapeutic agents, e.g., a compound of the present invention and a combination partner, are administered to a patient simultaneously, in parallel or sequentially as separate entities, without any specific time limit, such administration providing therapeutically effective levels of the two compounds in the patient's body. The latter also applies to cocktail therapy, e.g., administration of three or more therapeutic agents.

[0185] A subject (preferably a human) is "in need of" such treatment if the subject would benefit biologically, medically, or in quality of life from the treatment.

[0186] As used herein, the terms "inhibit," "inhibition," or "inhibiting" refer to the reduction or suppression of a given medical condition, symptom, or disorder or disease, or a significant decrease in the baseline activity of a biological activity or process.

[0187] As used herein, the terms "treat," "treatment," or "treating" any disease or disorder refers to alleviating or ameliorating the disease or disorder (i.e., slowing or arresting the occurrence of the disease or at least one of its clinical symptoms); or alleviating or improving at least one physical parameter or biomarker associated with the disease or disorder, including those that may not be discernible by the patient.

[0188] As used herein, the terms "prevent," "preventing," or "prevention" of any disease or disorder refers to the prophylactic treatment of the disease or disorder; or the delay in the onset or progression of the disease or disorder.

[0189] "Pharmaceutically acceptable" means that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients comprising the formulation and / or the mammal being treated therewith.

[0190] "Disorder" means, and is used interchangeably with, the term disease, condition, or illness, unless otherwise indicated.

[0191] "Administer," "administering," or "administration" means either directly administering to a subject a disclosed compound, or a pharma- ceutically acceptable salt or composition of a disclosed compound, or administering to a subject a prodrug derivative or analog of the compound, or a pharma- ceutically acceptable salt or composition of the compound, which is capable of forming an equivalent amount of the active compound in the subject's body.

[0192] "Compounds of the invention", "compounds of formula (I)", "compounds of the invention" and equivalent expressions (unless expressly stated otherwise) refer to compounds of formula (I) and (Ia) as described herein, where the context so permits, including salts thereof, particularly pharma- ceutically acceptable salts thereof, as well as stereoisomers (including diastereoisomers and enantiomers), rotamers, tautomers and isotopically labeled compounds (including deuterium ("D") substitutions).

[0193] In certain embodiments, the term "about" or "approximately" means within 20%, preferably within 10%, and more preferably within 5% of a given value or range.

[0194] As used herein, terms such as "a disorder or disease responsive to inhibition of the GIRK1 / 4 receptor" and "a disorder responsive to inhibition of the GIRK1 / 4 receptor" include, but are not limited to, cardiac arrhythmias, atrial fibrillation, bradyarrhythmia, bradycardia, heart block, sick sinus syndrome, parasympathetic hyperresponsiveness, primary aldosteronism, hypotension, and vasovagal syncope. EXAMPLES

[0195] The present invention is further illustrated by the following examples and synthesis schemes, which should not be construed as limiting the scope or spirit of the present invention to the specific procedures described herein. It should be understood that the examples are provided to illustrate specific embodiments, and no limitation to the scope of the present invention is intended thereby. It should be further understood that various other embodiments, modifications and equivalents thereof that may themselves suggest themselves to those skilled in the art can be used without departing from the spirit of the present invention and / or the scope of the appended claims.

[0196] The compounds of the present invention can be prepared by methods known in the art of organic synthesis. It is understood that in all of the methods, protecting groups for sensitive or reactive groups can be used as necessary in accordance with general principles of chemistry. Protecting groups are manipulated according to standard methods of organic synthesis (TW Green and PG M Huts (1999) Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons). These groups are removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art.

[0197] Reagents and solvents were used as received from commercial suppliers unless otherwise noted. Proton nuclear magnetic resonance (NMR) spectra were obtained on either a Bruker Avance spectrometer or a Varian Oxford 400 MHz spectrometer unless otherwise noted. NMR spectra are given in ppm (δ) and coupling constants, J, are reported in Hertz. Tetramethylsilane (TMS) was used as an internal standard. Chemical shifts are reported in ppm relative to dimethylsulfoxide (δ 2.50), methanol (δ 3.31), chloroform (δ 7.26) or other solvents as indicated in the NMR spectral data. A small amount of dried sample (2-5 mg) is dissolved in an appropriate deuterated solvent (1 mL). Mass spectra (ESI-MS) were collected using a Waters System (Acquity UPLC and Micromass ZQ mass spectrometer) or an Agilent-1260 Infinity (6120 Quadrupole); all masses reported are the m / z of the protonated parent ion unless otherwise noted. Chemical names were generated using ChemBioDraw Ultra v14 from CambridgeSoft.

[0198] Temperatures are given in °C. As used herein, unless otherwise specified, the term "room temperature" or "ambient temperature" means a temperature between 15°C and 30°C, e.g., between 20°C and 30°C, e.g., between 20°C and 25°C. Unless otherwise specified, all evaporations are carried out under reduced pressure, typically between about 15mmHg and 100mmHg (=20-133mbar). The structures of final products, intermediates and starting materials are confirmed by standard analytical methods, e.g., microanalysis, and spectroscopic characteristics, e.g., MS, IR, NMR. Abbreviations used are those commonly used in the art.

[0199] All starting materials, building blocks, reagents, acids, bases, dehydrating agents, solvents and catalysts utilized to synthesize the compounds of the present invention are either commercially available or can be prepared by organic synthesis methods known to those skilled in the art.

[0200] [Table 13]

[0201] [Table 14]

[0202] General synthesis scheme Exemplary compounds of formula (I) can be prepared as described below in Schemes B, C and D. The necessary intermediate F for Schemes B, C and D is prepared as described below in Scheme A.

[0203] As shown in Scheme A, pyridine A can be reacted with POCl in a suitable solvent such as DMF at a suitable temperature, typically between 0° C. and 90° C. (e.g., room temperature). 3 The aldehyde B can be chlorinated and formylated in a one-pot reaction with a deprotonated alkyne (e.g., a Grignard reagent) (where R 3is as defined herein) to give benzyl alcohol C. 3 (wherein x is as defined herein) is oxidized to the corresponding ketone under suitable oxidation conditions, such as Dess-Martin periodinane reagent, in a suitable solvent, such as DCM, at a suitable temperature, typically 0° C. to room temperature. 3 ) to give intermediate E (wherein X is F, Br or I and R 3 Intermediate E can be prepared by subjecting intermediate E to basic conditions (e.g., intermediate E (wherein X is F or I and R 3 is as defined herein) in DMF with triethylamine or intermediate E (wherein X is Br and R 3 annealed 4-pyridone F (wherein X is F, Br or I, and R is as defined herein) under NaOH in DCM; 3 is as defined herein). Scheme A: [ka]

[0204] Examples of compounds of general formula (Ia) can be prepared as described below in Scheme B. Scheme B: [ka]

[0205] As shown in Scheme B, intermediate F (wherein X is F or Br and R 3 is as defined herein) is R 2 -OH(in the formula, R 2can be converted to intermediate G by aromatic nucleophilic substitution with -OR, as defined herein. 1 is an intermediate G, where X is F or Br, and R 2 and R 3 is as defined herein), 1 -OH(in the formula, R 1 is as defined herein), to give compounds of formula (Ia), 1 , R 2 and R 3 is as defined herein) is obtained. 1 -OH and R 2 The -OH alcohols are commercially available or can be prepared according to the literature or by analogous methods. Further transformations, such as protecting group manipulations or amide formations, can be carried out either in the synthetic sequence to give further compounds of general formula (Ia), where R 1 and R 3 is as defined herein, and R' 2 is -NHC(O)R d and -C(O)NHR e (C 1 ~C 6 ) alkyl, (C 1 ~C 6 ) alkyl is optionally further substituted with one or more substituents independently selected from halo, -OH and -CN; R 2 is R' 2 ) is obtained.

[0206] Alternatively, intermediate G, where X is Br or I, and R 2 and R 3 is as defined herein) is PdCl 2 The boronic ester H can be converted to a phenol J (wherein R 2 and R 3is as defined herein). Intermediate J can be converted by nucleophilic substitution with a bromide or triflate in the presence of a suitable base to give compounds of general formula (Ia), 1 , R 2 and R 3 As shown in Scheme B, further transformations, such as protecting group manipulations or amide formations, can be carried out in any of the synthetic sequences to give further compounds of general formula (Ia), where R 1 and R 3 is as defined herein, and R' 2 is -NHC(O)R d and -C(O)NHR e (C 1 ~C 6 ) alkyl, (C 1 ~C 6 ) alkyl is optionally further substituted with one or more substituents independently selected from halo, -OH and -CN; R 2 is R' 2 ) is obtained. Scheme C: [ka]

[0207] According to Scheme D, intermediate F (wherein X is F) can be reacted with Pd 2 (dba) 3 can also be reacted with a stannane (e.g., vinyl- or allyl-tributylstannane) via Stille coupling in the presence of a suitable Pd catalyst such as A is vinyl or allyl, R 3 is as defined herein). 1 -OH(in the formula, R 1is as defined herein) to give intermediate L, which can be reacted with sodium alkylsulfonate R in a suitable solvent such as EtOH or AcOH. A 'SO 2 Na (wherein R A '-SO 2 (C 1 ~C 4 ) alkyl substituted (C 1 ~C 6 ) alkyl) to give a compound of general formula (Ib), A '-SO 2 (C 1 ~C 4 ) alkyl substituted (C 1 ~C 6 ) alkyl, R 1 and R 3 Alternatively, an alkene can be used to form an in situ terminal borane with 9-BBN, which can be reacted with Pd(PPh) to form intermediate F (where X is F). 3 ) 4 to afford intermediate M, B is -S(C 1 ~C 4 ) alkyl or -C(O)NHR c (C 1 ~C 6 ) alkyl, R 3 and R c is as defined herein). In the case of sulfide side chains, oxidation (e.g., H 2 O 2 ) to give the sulfone in a subsequent step. 1 -OH(in the formula, R 1 is as defined herein) to give compounds of general formula (Ic), B '-SO 2 (C 1 ~C 4 ) alkyl or -C(O)NHR c (C1 ~C 6 ) alkyl, R 1 , R 3 and R c is as defined herein). Scheme D: [ka]

[0208] The following LC-MS methods were used for characterization of the examples and intermediates.

[0209] LCMS method 1 System: Shimadzu LCMS 2020 Column: Synergi 2.5μ MAX-RP100 A Mercury Column temperature: 40℃ Gradient (time / %B): 0.1 / 5, 0.5 / 5, 1.0 / 95, 1.5 / 95, 2.0 / 5, 3.0 / 5 Eluent A: 0.1% HCO in water 2 H Eluent B: CH 3 CN Flow rate: 2.0mL / min Ion source: DUIS-ESI and APCI Atomization gas flow rate: 1.5L / min DL temperature: 250℃ Heating block temperature: 400℃

[0210] LCMS method 2 System: Shimadzu LCMS 2020 Column: Kinetex 2.6 μm, C18 100A, 30×3 mm. Column temperature: 40℃ Gradient (time / %B): 0.1 / 20, 0.25 / 20, 0.75 / 95, 1.75 / 95, 2 / 20, 2.5 / 20 Eluent A: 0.1% HCO in water 2 H Eluent B: CH 3 CN Flow rate: 1.0mL / min Ion source: DUIS-ESI and APCI Atomization gas flow rate: 1.5L / min DL temperature: 250℃ Heating block temperature: 400℃

[0211] LCMS method 3 System: Shimadzu LCMS 2020 Column: Synergi 2.5μ MAX-RP100 A Mercury Column temperature: 40℃ Gradient (time / %B): 0.1 / 5, 0.5 / 5, 1.0 / 95, 1.5 / 95, 2.0 / 5, 3.0 / 5 Eluent A: 0.1% HCO in water 2 H Eluent B: CH 3 CN Flow rate: 1.0mL / min Ion source: DUIS-ESI and APCI Atomization gas flow rate: 1.5L / min DL temperature: 250℃ Heating block temperature: 400℃

[0212] LCMS method 4 System: SCI EX API 3200 Column: Kinetex EVO C18 100A, 2.6 μm, 50 × 4.6 mm, Column temperature: 30℃ Gradient (time / %B): 0 / 30, 0.2 / 30, 0.7 / 95, 2.0 / 95, 2.5 / 30, 3.5 / 30 Eluent A: 0.1% HCO in water 2 H Eluent B: CH 3 0.1% HCO in CN 2 H Flow rate: 1.5mL / min Ion source: Turbospray Heating block temperature: 450℃

[0213] LCMS method 5 System: SCI EX API 2000 Column: Synergi 2.5μ MAX-RP100 A Mercury Column temperature: 30℃ Gradient (time / %B): 0 / 30, 0.5 / 30, 1.0 / 95, 1.5 / 95, 2.5 / 30, 3.0 / 30 Eluent A: 0.1% HCO in water 2 H Eluent B: CH 3 0.1% HCO in CN 2 H Flow rate: 2mL / min Ion source: Turbospray Heating block temperature: 450℃

[0214] LCMS method 6 System: Shimadzu LCMS 2020 Column: Synergi 2.5μ MAX-RP100 A Mercury Column temperature: 40℃ Gradient (time / %B): 0.1 / 5, 0.5 / 5, 1.0 / 95, 1.5 / 95, 2.0 / 5, 3.0 / 5 Eluent A: 0.1% HCO in water 2 H Eluent B: CH 3 CN Flow rate: 2.0mL / min Ion source: DUIS-ESI and APCI Atomization gas flow rate: 1.5L / min DL temperature: 250℃ Heating block temperature: 400℃

[0215] LCMS method 7 System: Agilent 1100 Column: Acquity UPLC BEH C18 Column, 2.1 x 30 mm, 1.7 μm column Oven temperature: 50℃ Gradient (time / %B): 0 min / 2, 0.1 min / 2 to 1.5 min / 98, 1.8 min / 98, 1.8 min / 98 to 1.9 min / 2, 2.0 min / 2 over 0.1 min Eluent A: 0.1% formic acid in water Eluent B: CH 3 0.1% formic acid in CN Flow rate: 1mL / min

[0216] Chiral HPLC Method 1 Column: Chiral PAL-IH (150 x 4.6 mm x 5 μM) Mobile phase: A: n-hexane, B: 0.1% HCOOH in ethanol:methanol (80:20) Isocratic: 70:30 (A:B) Flow rate: 1mL / min Diluent: Ethanol Column temperature: 25℃

[0217] Chiral HPLC Method 2 Column: Lux Cellulose (150 x 4.6 mm x 5 μM) Mobile phase: A: n-hexane, B: 0.1% HCOOH in ethanol:methanol (80:20) Isocratic: 70:30 (A:B) Flow rate: 1mL / min Diluent: Ethanol Column temperature: 25℃

[0218] Synthesis of Intermediate F (F1, F2 and F3) Synthesis of 5,8-dichloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-1,6-naphthyridin-4(1H)-one (Intermediate F1) [ka] Step 1: 2,4,5-Trichloronicotinaldehyde [ka] Phosphoryl trichloride (475 mL) was added dropwise to DMF (750 mL) at 0° C. under nitrogen. The resulting mixture was stirred at 0° C. for 1 h. Then, 5-chloropyridine-2,4-diol (150 g, 1.03 mol) was added. The mixture was stirred at 90° C. for 12 h. LCMS showed the reaction was complete. The reaction mixture was cooled to 0° C., poured into 2000 mL of ice water, and extracted with 3×1000 mL of DCM. The organic layers were combined, washed with brine, dried over anhydrous sodium sulfate, and concentrated. The residue was applied to a silica gel column with ethyl acetate / petroleum ether (1:9). This gave 131 g (48%) of 2,4,5-trichloronicotinaldehyde as a yellow solid. ESI-MS m / z: 210.0 [M+H] + ; 1 H NMR (400 MHz, DCM-d 2 )δ ppm=10.43(s,1H), 8.61(s,1H).

[0219] Step 2: 1-(2,4,5-trichloropyridin-3-yl)but-2-yn-1-ol [ka] To a solution of 2,4,5-trichloronicotinaldehyde (117 g, 0.56 mol) in THF (1000 mL) was added prop-1-yn-1-ylmagnesium bromide (1.2 L, 0.62 mol) dropwise at -60°C and stirring was continued at -60°C for 1 h. LCMS showed the reaction was complete. The reaction mixture was quenched with ammonium chloride solution (1000 mL) below -20°C. The resulting solution was extracted with ethyl acetate. The mixture was diluted with H 2 O and brine, dried over anhydrous sodium sulfate and concentrated. This gave 120 g (86%) of 1-(2,4,5-trichloropyridin-3-yl)but-2-yn-1-ol as a yellow solid. ESI-MS m / z: 250.0 [M+H] + ; 1 H NMR (400 MHz, DCM-d 2)δ ppm=8.42(s,1H), 6.13(s,1H), 3.11(bs,1H), 1.90(s,3H).

[0220] Step 3: 1-(2,4,5-trichloropyridin-3-yl)but-2-yn-1-one [ka] To a solution of 1-(2,4,5-trichloropyridin-3-yl)but-2-yn-1-ol (150 g, 0.60 mol) in DCM (1000 mL) was added Dess-Martin reagent (280 g, 0.66 mol) at 0°C. The mixture was stirred at room temperature for 2 h. LCMS showed the reaction was complete. The solid was filtered off. The filtrate solution was washed with sodium sulfite solution and sodium carbonate solution. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. This gave 1-(2,4,5-trichloropyridin-3-yl)but-2-yn-1-one (160 g crude product) as a brown solid. ESI-MS m / z: 248.0 [M+H] + ; 1 H NMR (400 MHz, DCM-d 2 )δ ppm=8.51(s,1H), 2.16(s,3H).

[0221] Step 4: (E)-3-((2,6-dichloro-4-fluorophenyl)amino)-1-(2,4,5-trichloropyridin-3-yl)but-2-en-1-one [ka] A solution of 1-(2,4,5-trichloropyridin-3-yl)but-2-yn-1-one (160 g, 0.64 mol), 4-fluoro-2,6-dichloroaniline (115 g, 0.64 mol) in DCM (1200 mL) was diluted with AlCl 3(102 g, 0.76 mol) was added at 5° C. Stirring was continued at room temperature for 2 h. LCMS showed the reaction was complete. The solution was quenched with water at 5° C. The resulting solution was extracted with ethyl acetate (2×1000 mL) and the organic layers were combined. The organic layers were dried over anhydrous sodium sulfate and concentrated. This gave 340 g (crude product) (E)-3-((2,6-dichloro-4-fluorophenyl)amino)-1-(2,4,5-trichloropyridin-3-yl)but-2-en-1-one as a brown solid. The crude material was used directly in the next step. ESI-MS m / z: 427 [M+H] + .

[0222] Step 5: 5,8-Dichloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-1,6-naphthyridin-4(1H)-one [ka] To a solution of (E)-3-((2,6-dichloro-4-fluorophenyl)amino)-1-(2,4,5-trichloropyridin-3-yl)but-2-en-1-one (340 g crude product) in DMF (1000 mL) was added TEA (252 g, 2.5 mol) at room temperature. The mixture was stirred at 60° C. for 1 h. LCMS showed the reaction was complete. The solution was quenched with 2 L of water and extracted with ethyl acetate (3×1000 mL). The combined organic layers were washed with water and brine, dried over anhydrous sodium sulfate and concentrated. The residue was applied to a silica gel column with ethyl acetate / petroleum ether (3:7) as eluent. This gave 162.6 g (64% for two steps) of 5,8-dichloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-1,6-naphthyridin-4(1H)-one as a light brown solid. ESI-MS m / z: 391.0 [M+H] + ; 1 H NMR (300 MHz, chloroform-d 3 )δ ppm=8..31(s,1H), 7.26(d,J=12.3Hz, 2H), 6.47(s,1H), 1.99(m,3H).

[0223] Synthesis of 1-(4-bromo-2,6-dichlorophenyl)-5,8-dichloro-2-methyl-1,6-naphthyridin-4(1H)-one (Intermediate F2) [ka] Steps 1-3: See synthesis of intermediate F1

[0224] Step 4: (E)-3-((4-bromo-2,6-dichlorophenyl)amino)-1-(2,4,5-trichloropyridin-3-yl)but-2-en-1-one [ka] A solution of 1-(2,4,5-trichloropyridin-3-yl)but-2-yn-1-one (120 g, 0.49 mol), 4-bromo-2,6-dichloroaniline (118 g, 0.49 mol) in DCM (800 mL) was diluted with AlCl 3 (78 g, 0.58 mol) was added at 5° C. Stirring was continued at room temperature for 2 h. LCMS showed the reaction was complete. The solution was quenched with water at 5° C. The resulting solution was extracted with ethyl acetate (2×1000 mL) and the organic layers were combined. The organic layers were dried over anhydrous sodium sulfate and concentrated. This gave 240 g of (crude product) (E)-3-((4-bromo-2,6-dichlorophenyl)amino)-1-(2,4,5-trichloropyridin-3-yl)but-2-en-1-one as a brown solid. The crude product was used directly in the next step. ESI-MS m / z: 487 [M+H] + .

[0225] Step 5: 1-(4-bromo-2,6-dichlorophenyl)-5,8-dichloro-2-methyl-1,6-naphthyridin-4(1H)-one [ka] To a solution of (E)-3-((4-bromo-2,6-dichlorophenyl)amino)-1-(2,4,5-trichloropyridin-3-yl)but-2-en-1-one (240 g crude product) in DCM (270 mL) was added NaOH (2.83 g, 1.2 equiv.). The reaction mixture was stirred at 15-25 °C for 8-12 h. After the reaction was complete, the mixture was concentrated to 50-60 g. Toluene (143 mL) was charged. The mixture was concentrated to 50-60 g. Toluene (289 mL) was charged. The organic layer was washed with water (3 x 289 mL). The aqueous layers were combined and extracted with toluene (289 mL). The combined toluene layers were stirred with activated charcoal (1.45 g, 50-60 °C, 2-3 h), filtered, and concentrated. After crystallization in toluene / heptane (v / v=1 / 1), 1-(4-bromo-2,6-dichlorophenyl)-5,8-dichloro-2-methyl-1,6-naphthyridin-4(1H)-one was obtained as a light brown solid in 69% yield. ESI-MS m / z: 452 [M+H] + ; 1 H NMR (300 MHz, chloroform-d 3 )δ ppm=8..33(s,1H), 7.67(s,2H), 6.49(d,J=0.6Hz, 1H), 1.99(m,3H).

[0226] Synthesis of 5,8-dichloro-1-(2,6-dichloro-4-iodophenyl)-2-methyl-1,6-naphthyridin-4(1H)-one (Intermediate F3) [ka] Intermediate F3 was prepared in a similar manner to intermediates F1 and F2, except that 2,6-dichloro-4-iodoaniline was used. ESI-MS m / z: 498.8 [M+H] + ; 1 H NMR (300MHz, DMSO-d6) δ ppm=8..52(s,1H), 8.22(s,2H), 6.61(s,1H), 1.94(s,3H).

[0227] Synthesis of compounds of formula (I) The following examples of compounds of either Formula (Ia) or Formula (Ib) or Formula (Ic) were prepared from intermediates F1 and F2 described below.

[0228] Example 1: 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide (Compound C-1) [ka] Step 1: 3-((8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide To 5,8-dichloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-1,6-naphthyridin-4(1H)-one (Intermediate F1, 3.5 g, 8.927 mmol) and 3-hydroxy-N-methylpropanamide (1.38 g, 13.39 mmol) in acetonitrile (40 mL) was added potassium carbonate (3.08 g, 22.31 mmol), DMAP (327.1 mg, 2.678 mmol) and the mixture was heated at 80° C. for 16 h. The progress of the reaction was monitored by TLC until complete consumption of the starting material. The color of the reaction mixture changed from light brown to dark brown. The mixture was quenched with cold water, extracted with ethyl acetate (3×25 mL), dried and concentrated. The crude material was purified by flash chromatography using 1% MeOH in dichloromethane as eluent to give the desired product as an off-white solid (2.8 g, 69%).

[0229] Step 2: 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide To 3-((8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide (2.8 g; 6.126 mmol) and anhydrous ethylene glycol (1.521 g; 24.506 mmol) in DMF (30 mL) was added cesium carbonate (4.99 g, 15.315 mmol) and the mixture was stirred at room temperature for 4 h. The progress of the reaction was monitored by TLC. The color of the reaction mixture changed from light brown to dark brown. The reaction mixture was quenched with ice-cold water and extracted with ethyl acetate (3×25 mL). The organic layer was dried and concentrated to give the crude product. The crude material was purified by flash chromatography using 3% MeOH in dichloromethane as eluent to give the desired product as an off-white solid (1.4 g, 46%) with an additional 20% of the starting material recovered. A second chromatography step using the same eluent was required to obtain 99% pure material as a white powder. C-1: HRMS m / z: calculated 500.05413 [M+H] + , actual value 500.05482. 1 H NMR (600MHz, DMSO-d6)δ ppm=8.24(s,1H), 8.23(q,1H), 7.36(s,2H), 6.48(s,1H), 4.96(s,1H), 4.53(t,2H) ), 4.15(t,2H), 3.72(t,2H), 2.78(s,3H), 2.62(d,3H), 2.60(t,2H), 1.91(m,3H). 13 C NMR (150MHz, DMSO-d6)δ ppm=175.0, 170.1161.8, 150.9, 149.8, 145.0, 135.8, 126.8, 117.0, 115.0110.4, 109.8, 71.1, 63.3, 59.2, 35.2, 25.6, 20.0.

[0230] Crystalline forms of compound C-1 were isolated as shown below in modifications A-1, A-2, A-3, A-4, A-5, A-6, A-7, A-8, A-9, A-10, A-11, A-12 and A-13. The crystal forms were characterized by X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), ultra performance liquid chromatography (UPLC) and NMR using analytical methods as shown in Table 2 below.

[0231] The XRPD profile for each crystalline form is shown in the figures. A list of characteristic XRPD peaks is shown in the tables below and described in the figures. The peaks listed herein are given in 2θ° (±0.1°). As will be appreciated by those skilled in the art, the relative intensity of the various peaks in the tables shown below may vary due to several factors, such as, for example, the orientation effect of the crystals in the X-ray beam or the purity of the material being analyzed or the crystallinity of the sample. The peak positions may also shift with respect to changes in sample height, but the peak positions remain substantially as defined in the given tables. Those skilled in the art will also appreciate that measurements using different wavelengths will result in different shifts according to the Bragg equation -nλ=2d sinθ. Such alternative XRPD patterns generated by the use of alternative wavelengths will nevertheless represent the same material.

[0232] [Table 15]

[0233] [Table 16]

[0234] Modification A-1: ​​Free crystalline form of 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide (compound C-1). Compound C-1 (2.0 g) from Example 1 was dissolved in a water / ethanol solution at a temperature below 35° C. The resulting solution was filtered to remove undissolved impurities. Seed crystals were obtained after a first portion of water was added into the reactor at a temperature of 25° C. under stirring. A second portion of water was added and the solid so obtained was filtered, washed and dried at 50° C. under reduced pressure at 0-100 mbar. The solid residue (1.77 g) was recovered with a purity of 99.52% (UPLC) and analyzed by XRPD, DSC, TGA and NMR. The physicochemical properties are presented in Table 3.

[0235] [Table 17]

[0236] The DSC thermogram of modification A-1 of Example 1 is shown in Figure A1-2. The TGA of modification A-1 of Example 1 is shown in Figure A1-3. The DSC data showing the melting transition and total water loss (Loss on Drying - LOD) of modification A-1 as measured by TGA are presented in Table 3.

[0237] The XRPD pattern of modification A-1 of Example 1 is shown in Figure A1-1. The XRPD peaks when measured at a temperature of about 22°C using CuKα radiation having a wavelength of 1.5418 Å are as shown in the table below.

[0238] [Table 18]

[0239] Modification A-2: Hydrate crystal form of 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide (compound C-1). Compound C-1 (2.0 g) of Example 1 was dissolved in a water / ethanol solution at a temperature below 35° C. The resulting solution was filtered to remove undissolved impurities. Seed crystals were obtained after a first portion of water was added into the reactor at a temperature of 25° C. under stirring. A second portion of water was added dropwise to the suspension at a temperature of 16° C. over a period of 10 hours, and the resulting suspension was kept at 16° C. for a period of 13 hours. The solid thus obtained was then filtered, washed, and dried at 45° C. under reduced pressure at 40 mbar. The solid residue (1.94 g) was recovered with a purity of 99.59% (UPLC) and analyzed by XRPD, DSC, TGA, and NMR. The physicochemical properties are presented in Table 3.

[0240] The DSC thermogram of modification A-2 of Example 1 is shown in Figure A2-2. The TGA of modification A-2 of Example 1 is shown in Figure A2-3. The DSC data showing the melting transition and total water loss (Loss on Drying - LOD) of modification A-2 as measured by TGA are presented in Table 3.

[0241] The XRPD pattern of modification A-2 of Example 1 is shown in Figure A2-1. The XRPD peaks when measured at a temperature of about 22°C using CuKα radiation having a wavelength of 1.5418 Å are as shown in the table below.

[0242] [Table 19]

[0243] Modification A-3: Hydrate crystal form of 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide (compound C-1). Compound C-1 of Example 1 was transferred to a 75% relative humidity chamber and kept for about 24 hours to obtain a solid residue (5.1 g). It was recovered with a purity of 99.09% (UPLC) and analyzed by XRPD, DSC, TGA and NMR. The physicochemical properties are shown in Table 3.

[0244] The DSC thermogram of modification A-3 of Example 1 is shown in Figure A3-2. The TGA of modification A-3 of Example 1 is shown in Figure A3-3. The DSC data showing the melting transition and total water loss (Loss on Drying - LOD) of modification A-3 as measured by TGA are presented in Table 3.

[0245] The XRPD pattern of modification A-3 of Example 1 is shown in Figure A3-1. The XRPD peaks when measured at a temperature of about 22°C using CuKα radiation having a wavelength of 1.5418 Å are as shown in the table below.

[0246] [Table 20]

[0247] Modification A-4: Hydrate crystal form of 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide (compound C-1). Compound C-1 (10.0 g) of Example 1 was suspended in 60 mL of methanol / water mixture at a temperature of 40° C. The resulting suspension was stirred at 60° C. to obtain a clear solution. The solution was cooled to 50° C. and stirred for 1 h. Then, the solution was cooled to 40° C. for 10 h. The solid thus obtained was filtered, washed and dried under reduced pressure at room temperature. The solid residue was recovered with a purity of 99.57% (UPLC) and analyzed by XRPD, DSC, TGA and NMR. The physicochemical properties are presented in Table 3.

[0248] The DSC thermogram of modification A-4 of Example 1 is shown in Figure A4-2. The TGA of modification A-4 of Example 1 is shown in Figure A4-3. The DSC data showing the melting transition and total water loss (Loss on Drying - LOD) of modification A-4 by TGA are presented in Table 3.

[0249] The XRPD pattern of modification A-4 of Example 1 is shown in Figure A4-1. The XRPD peaks when measured at a temperature of about 22°C using CuKα radiation having a wavelength of 1.5418 Å are as shown in the table below.

[0250] [Table 21]

[0251] Modification A-5: hydrate crystal form of 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide (compound C-1) The hydrate crystal form of modification A-4 of Example 1 was kept at 80° C. under 11% relative humidity for one week. The solid residue was analyzed by XRPD, DSC, TGA and NMR. The physicochemical properties are presented in Table 3.

[0252] The DSC thermogram of modification A-5 of Example 1 is shown in Figure A5-2. The TGA of modification A-5 of Example 1 is shown in Figure A5-3. The DSC data showing the melting transition and total water loss (loss on drying - LOD) of modification A-5 by TGA are presented in Table 3.

[0253] The XRPD pattern of modification A-5 of Example 1 is shown in Figure A5-1. The XRPD peaks when measured at a temperature of about 22°C using CuKα radiation having a wavelength of 1.5418 Å are as shown in the table below.

[0254] [Table 22]

[0255] Modification A-6: solvate of 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide (compound C-1) with cyclopentanone Compound C-1 of Example 1 was equilibrated with cyclopentanone for 14 days at 4° C. The solid residue was collected and analyzed by XRPD, DSC, TGA, UPLC and NMR.

[0256] Modification A-6 is a highly crystalline form with a melting point of about 157° C. The desolvation temperature is about 102° C. It shows a weight loss of 4.6% by TGA at 150° C. The XRPD pattern as measured at a temperature of about 22° C. using CuKα radiation with a wavelength of 1.5418 Å is shown in FIG. A6-1.

[0257] Modification A-7: Solvate of 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide (compound C-1) with methanol Compound C-1 of Example 1 was equilibrated with methanol or methanol / water (97:3 v / v) for 14 days at 4° C. The solid residue was collected and analyzed by XRPD, DSC, TGA, UPLC and NMR.

[0258] Modification A-7 is a highly crystalline form with a melting point of about 157° C. The desolvation temperature is about 79° C. It shows a weight loss of 3.7% by TGA at 105° C. The XRPD pattern as measured at a temperature of about 22° C. using CuKα radiation with a wavelength of 1.5418 Å is shown in FIG. A7-1.

[0259] Modification A-8: Solvate of 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide (compound C-1) with pyridine Compound C-1 of Example 1 was equilibrated with pyridine at 4° C. for 7 days. The solid residue was collected and analyzed by XRPD, DSC, TGA, UPLC and NMR. The XRPD pattern measured at a temperature of about 22° C. using CuKα radiation with a wavelength of 1.5418 Å is shown in Figure A8-1.

[0260] Cocrystals of compound C-1 (modifications A-9, A-10, A-11, A-12 and A-13) Compound C-1 of Example 1 was mixed with an appropriate amount of co-crystal former. The resulting mixture was dissolved / slurried in a respective solvent at 50° C. and cooled to room temperature until precipitation occurred. After cooling, the resulting solution was evaporated to dryness to obtain a solid. The solid residue was collected and analyzed by XRPD, DSC, TGA, UPLC and NMR. The physicochemical properties of the co-crystal of compound C-1 are presented in Table 4.

[0261] [Table 23]

[0262] Modification A-9: Cocrystal of 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide (compound C-1) with phosphoric acid (1:0.76 molar ratio) Compound C-1 (0.2 g) of Example 1 and 1.0 equivalent of phosphoric acid were dissolved in 4.0 mL of acetonitrile:H 2 The resulting mixture was dissolved in 0 (95:5 v / v) at 50° C. and cooled to room temperature to obtain a co-crystal of compound C-1 with phosphoric acid in a molar ratio of 1:0.76.

[0263] The DSC thermogram of modification A-9 of Example 1 is shown in Figure A9-2. The TGA of modification A-9 of Example 1 is shown in Figure A9-3. The DSC data showing the melting transition and total water loss (Loss on Drying - LOD) of modification A-9 as measured by TGA are presented in Table 4.

[0264] The XRPD pattern of modification A-9 of Example 1 is shown in Figure A9-1. The XRPD peaks when measured at a temperature of about 22°C using CuKα radiation having a wavelength of 1.5418 Å are as shown in the table below.

[0265] [Table 24]

[0266] Modification A-10: Cocrystal of 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide (compound C-1) with phosphoric acid (1:0.97 molar ratio) Compound C-1 (30 mg) of Example 1 and 1.5 equivalents of phosphoric acid were dissolved in 0.6 mL of acetone. The resulting mixture was dissolved at 50° C. and cooled to room temperature to obtain a co-crystal of compound C-1 with phosphoric acid in a molar ratio of 1:0.97.

[0267] The DSC thermogram of modification A-10 of Example 1 is shown in Figure A10-2. The TGA of modification A-10 of Example 1 is shown in Figure A10-3. The DSC data showing the melting transition and total water loss (Loss on Drying - LOD) of modification A-10 as measured by TGA are presented in Table 4.

[0268] The XRPD pattern of modification A-10 of Example 1 is shown in Figure A10-1. The XRPD peaks when measured at a temperature of about 22°C using CuKα radiation having a wavelength of 1.5418 Å are as shown in the table below.

[0269] [Table 25]

[0270] Modification A-11: Cocrystal of 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide (compound C-1) with benzoic acid (1:1.01 molar ratio) Compound C-1 (60 mg) and 28 mg (2 equivalents) of benzoic acid were dissolved in 0.30 mL of isopropanol. The resulting mixture was dissolved at 50° C. and cooled to room temperature to obtain a co-crystal of compound C-1 with benzoic acid in a molar ratio of 1:1.01.

[0271] The DSC thermogram of modification A-11 of Example 1 is shown in Figure A11-2. The TGA of modification A-11 of Example 1 is shown in Figure A11-3. The DSC data showing the melting transition and total water loss (Loss on Drying - LOD) of modification A-11 as measured by TGA are presented in Table 4.

[0272] The XRPD pattern of modification A-11 of Example 1 is shown in Figure A11-1. The XRPD peaks when measured at a temperature of about 22°C using CuKα radiation having a wavelength of 1.5418 Å are as shown in the table below.

[0273] [Table 26]

[0274] Modification A-12: Cocrystal of 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide (compound C-1) with succinic acid (1:1.02 molar ratio) Compound C-1 (1.0 g) and 2 equivalents of succinic acid were dissolved in 5.2 mL of isopropanol. The resulting mixture was dissolved at 50° C. and cooled to room temperature to obtain a co-crystal of compound C-1 with succinic acid in a molar ratio of 1:1.02.

[0275] The DSC thermogram of modification A-12 of Example 1 is shown in Figure A12-2. The TGA of modification A-12 of Example 1 is shown in Figure A12-3. The DSC data showing the melting transition and total water loss (Loss on Drying - LOD) of modification A-12 as measured by TGA are presented in Table 4.

[0276] The XRPD pattern of modification A-12 of Example 1 is shown in Figure A12-1. The XRPD peaks when measured at a temperature of about 22°C using CuKα radiation having a wavelength of 1.5418 Å are as shown in the table below.

[0277] [Table 27]

[0278] Modification A-13: Cocrystal of 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide (compound C-1) with saccharin (1:0.50 molar ratio) Compound C-1 (1.0 g) and 1.5 equivalents of saccharin were dissolved in 20.0 mL of isopropanol. The resulting mixture was dissolved at 50° C. and cooled to room temperature to obtain a co-crystal of compound C-1 with saccharin in a molar ratio of 1:0.50.

[0279] The DSC thermogram of modification A-13 of Example 1 is shown in Figure A13-2. The TGA of modification A-13 of Example 1 is shown in Figure A13-3. The DSC data showing the melting transition and total water loss (Loss on Drying - LOD) of modification A-13 as measured by TGA are presented in Table 4.

[0280] The XRPD pattern of modification A-13 of Example 1 is shown in Figure A13-1. The XRPD peaks when measured at a temperature of about 22°C using CuKα radiation having a wavelength of 1.5418 Å are as shown in the table below.

[0281] [Table 28]

[0282] Example 2: 2-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-(2-hydroxyethyl)acetamide (Compound C-2) [ka] Step 1: Methyl 2-((1-(4-bromo-2,6-dichlorophenyl)-8-chloro-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)acetate CH 3 To a stirred solution of 1-(4-bromo-2,6-dichlorophenyl)-5,8-dichloro-2-methyl-1,6-naphthyridin-4(1H)-one (Intermediate F2, 2.5 g, 2.21 mmol) in CN (25 mL) was added methyl glycolate (0.24 g, 2.65 mmol), potassium carbonate (0.92 g, 6.62 mmol) and DMAP (0.09 g, 0.66 mmol). The resulting reaction mixture was stirred at 80° C. for 12 h. The reaction mixture was filtered off and the CH 3 Rinsed with CN. The organic layer was concentrated under reduced pressure. The residue was purified by MPLC using a 40 g silica gel column and 10-65% EtOAc in hexanes to give the title product as an off-white solid (2.4 g, 82% yield). ESI-MS m / z: 504.8 [M+H] + (Rt=1.55 min, LC-Method 6).

[0283] Step 2: (3,5-dichloro-4-(8-chloro-5-(2-methoxy-2-oxoethoxy)-2-methyl-4-oxo-1,6-naphthyridin-1(4H)-yl)phenyl)boronic acid In a sealed screw-cap tube, a degassed (with argon) solution of methyl 2-((1-(4-bromo-2,6-dichlorophenyl)-8-chloro-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)acetate (2.3 g, 4.55 mmol) in 1,4-dioxane (25 mL) was added with bis(pinacolato)diboron (1.73 g, 6.82 mmol), potassium acetate (0.67 g, 6.82 mmol), PdCl 2 (dppf) and DCM (0.37 g, 0.45 mmol) were added. The reaction mixture was stirred at 90° C. for 8 h. The reaction mixture was filtered through a pad of Celite and rinsed with 1,4-dioxane. The filtrate was concentrated under reduced pressure to give the crude title product (2.14 g, crude). ESI-MS m / z: 470.80 [M+H] + (Rt=1.41 min, LC-Method 1).

[0284] Step 3: Methyl 2-((8-chloro-1-(2,6-dichloro-4-hydroxyphenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)acetate MeOH:H at 0°C 2 To a solution of (3,5-dichloro-4-(8-chloro-5-(2-methoxy-2-oxoethoxy)-2-methyl-4-oxo-1,6-naphthyridin-1(4H)-yl)phenyl)boronic acid (1.94 g, 4.11 mmol) in 2H2O (10 mL:10 mL) was added Montmorillonite K10 (1.69 g, 6.17 mmol) and 30% hydrogen peroxide (10 mL) dropwise at the same temperature. The solution was stirred at room temperature for 2 h. The reaction mixture was concentrated under reduced pressure to give the crude product. The crude product was purified by MPLC using a 24.0 g silica gel column and 1-5% MeOH in dichloromethane to give the title product as a brown solid (1.3 g, yield: 71%). ESI-MS m / z: 442.90 [MH] +(Rt=1.43 min, LC-Method 6).

[0285] Step 4: 2-((8-chloro-1-(2,6-dichloro-4-hydroxyphenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)acetic acid To a solution of methyl 2-((8-chloro-1-(2,6-dichloro-4-hydroxyphenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)acetate (0.5 g, 1.13 mmol) in 1,2-dichloroethane (6 mL) was added trimethyltin hydroxide (2.05 g, 11.29 mmol). The so obtained solution was stirred at room temperature for 5 min and then at 80° C. for 12 h. The volatiles were evaporated under reduced pressure to give a residue. The residue was diluted with 10% KHSO 4 The mixture was acidified with 10% MeOH in dichloromethane and extracted with 10% MeOH in dichloromethane. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the desired product as a light brown solid (0.23 g, yield: 42%). ESI-MS m / z: 429.00 [M+H] + (Rt=1.38 min, LC-Method 6).

[0286] Step 5: N-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-((8-chloro-1-(2,6-dichloro-4-hydroxyphenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)acetamide To a solution of 2-((8-chloro-1-(2,6-dichloro-4-hydroxyphenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)acetic acid (0.2 g, 0.48 mmol) in DMF (3 mL) was added HATU (0.36 g, 0.95 mmol). The so obtained solution was stirred at room temperature for 5 min. To this solution was added 2-((tert-butyldimethylsilyl)oxy)ethan-1-amine (0.1 g, 0.57 mmol) and DIPEA (0.15 g, 1.19 mmol) and the obtained solution was stirred at room temperature for 12 h. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the title product as a light brown solid (0.22 g, yield: 79%). ESI-MS m / z: 586.15 [M+H] + (Rt=1.63 min, LC-Method 6).

[0287] Step 6: N-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)acetamide To a solution of N-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-((8-chloro-1-(2,6-dichloro-4-hydroxyphenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)acetamide (0.22 g, 0.38 mmol) in DMF (3 mL) was added silver carbonate (0.31 g, 1.12 mmol) and 2-bromoethanol (0.07 g; 0.56 mmol). The resulting reaction mixture was stirred at 80° C. for 12 h. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude product. The crude product was purified by MPLC using a 12.0 g silica gel column and 20-60% EtOAc in hexane to give the title product as a light brown solid (0.13 g, yield: 56%). ESI-MS m / z: 630.15 [M+H] +(Rt=1.59 min, LC-Method 6).

[0288] Step 7: 2-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-(2-hydroxyethyl)acetamide To a solution of N-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)acetamide (0.13 g, 0.21 mmol) in dry dioxane (2 mL) was added 4.0 HCl in 1,4-dioxane (2 mL) at 0° C. The solution so obtained was stirred at ambient temperature for 1 h. The volatiles were evaporated under reduced pressure to give a residue. The residue was dissolved in ethyl acetate and washed with saturated sodium bicarbonate solution. The organic layer was washed with brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude product. The crude product was purified by preparative HPLC (column: X SELECT (250 mm×19.0 mm, 5.0 μm); mobile phase: 0.02% NH in water 4 C-2: ESI-MS m / z: 516.05 [M+H]. The fractions were lyophilized to give the title product as an off-white powder (0.046 g, yield: 30%). C-3: ESI-MS m / z: 516.05 [M+H]. + (Rt=1.35 min, LC-Method 6); 1 H NMR (300MHz, chloroform-d3)δ ppm=8.21(s,1H), 7.27(s,2H), 6.55(s,1H), 4.92(s,2H), 4.18(t,J=4.2Hz, 2H), 3.92(t,J=4.5Hz, 2H), 3.71(t,J=6.0Hz, 2H), 3.49(t,J=6.0Hz, 2H), 2.04(S, 3H).

[0289] Example 3: 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxy-2-methylpropoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide (Compound C-3) [ka] Step 1: 3-((8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide A solution of 5,8-dichloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-1,6-naphthyridin-4(1H)-one (Intermediate F1, 1.0 g, 2.55 mmol) in acetonitrile (10 mL) was added with 3-hydroxy-N-methylpropanamide (0.32 g, 3.06 mmol), K 2 CO 3 (0.88 g, 6.38 mmol) and DMAP (0.09 g, 0.77 mmol) were added. The reaction mixture was stirred at 80° C. for 16 h. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with brine and added with Na 2 SO 4 The crude product was purified by MPLC using a 40 g Silicycle cartridge and 0-2% MeOH in dichloromethane as eluent to give the title product as an off-white solid (0.78 g, yield: 67%). ESI-MS m / z: 458.1 [M+1] + (Rt=1.40 min, LC-Method-5).

[0290] Step 2: 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxy-2-methylpropoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide To a stirred solution of 3-((8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide (0.78 g, 1.71 mmol) in DMF (8 mL) was added 2-methylpropane-1,2-diol (0.46 g, 5.12 mmol) and Cs 2 CO 3 (1.67 g, 5.12 mmol) was added. The resulting reaction mixture was stirred at room temperature for 4 h. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with brine and added with Na 2 SO 4 The crude product was purified by MPLC using a 40 g Silicycle cartridge and 0-2% MeOH in dichloromethane as eluent to give the title product as an off-white solid (0.22 g, yield: 24%). C-3: ESI-MS m / z: 527.90 [M+H] + (Rt=1.42 min, LC-Method-6). 1 H NMR (400MHz, methanol-d4)δ ppm=8.19(s,1H), 7.27(s,2H), 6.51(s,1H), 4.66(t,J=5.6Hz, 2H), 3.91(s,2H), 2.78(s,3H), 2.76(t,J=6.0Hz, 2H), 2.03(s,3H), 1.33(s,6H).

[0291] Example 4: 2-((8-chloro-1-(2,6-dichloro-4-(2-hydroxy-2-methylpropoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylacetamide (Compound C-4) [ka] Step 1: 2-((8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylacetamide To a stirred solution of 5,8-dichloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-1,6-naphthyridin-4(1H)-one (Intermediate F1, 0.3 g, 0.76 mmol) in acetonitrile (8 mL) was added K 2 CO 3 (0.31 g, 2.29 mmol) DMAP (0.03 g, 0.22 mmol) and 2-hydroxy-N-methylacetamide (0.1 g, 1.14 mmol) were added. The reaction mixture was heated at 80° C. for 16 h. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with brine and diluted with Na 2 SO 4 The crude product was purified by MPLC using a 12 g Silicycle cartridge and 0-2% MeOH in dichloromethane as eluent to give the title product as a white solid (0.2 g, yield: 59%). ESI-MS m / z: 444.0 [M+H] + (Rt=1.48 min, LC-Method 6).

[0292] Step 2: 2-((8-chloro-1-(2,6-dichloro-4-(2-hydroxy-2-methylpropoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylacetamide A stirred solution of 2-((8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylacetamide (0.13 g, 0.29 mmol) in DMF (5 mL) was diluted with Cs 2 CO 3 (0.28 g, 0.87 mmol) and 2-methylpropane-1,2-diol (0.04 g, 0.43 mmol) were added. The reaction mixture was stirred at ambient temperature for 16 h. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with brine and diluted with Na 2 SO 4The crude product was purified by MPLC using a 12 g Silicycle cartridge and 0-5% MeOH in dichloromethane as eluent as well as preparative HPLC (Column: X SELECT C-18 (250 mm×19 mm, 5.0 μm); Mobile phase: 0.1% formic acid in water and acetonitrile; Gradient elution) to give the title product as an off-white solid (0.023 g, Yield: 15%). C-4: ESI-MS m / z: 514.05 [M+H] + (Rt=1.42 min, LC-Method 6); 1 H NMR (300MHz, methanol-d4) δ ppm=8.21(s,1H), 7.28(s,2H), 6.55(s,1H), 4.91(s,2H), 3.91(s,2H), 2.89(s,3H), 2.05(s,3H), 1.33(s,6H).

[0293] Example 5: 2-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylacetamide (Compound C-5) [ka] 0.027 g (yield: 22%) of off-white powder of Example 5 was prepared in a similar manner to Example 4 using the intermediate of Step 1 of Example 4 and ethylene glycol. C-5: ESI-MS m / z: 486.05 [M+H] + (Rt=1.38 min, LC-Method 6); 1 H NMR (400MHz, chloroform-d3)δ ppm=8.8(brs,1H), 8.10(s,1H), 7.03(s,2H), 6.44(s,1H), 4.91(s,2H), 4.17(t,J= 4.4Hz, 2H), 4.05(t,J=5.2Hz, 2H), 2.98(d,J=4.8Hz, 3H), 2.08(t,1H), 1.97(s,3H).

[0294] Example 6: (R)-3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxypropoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide (Compound C-6) [ka] To a stirred solution of 3-((8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide (0.4 g, 0.87 mmol) [Step 1 of Example 3)] in DMF (10 mL) was added (R)-propane-1,2-diol (0.17 g, 1.31 mmol) and Cs 2 CO 3 (0.09 g, 2.62 mmol) was added. The reaction mixture was stirred at 50° C. for 3 h. The reaction mixture was partitioned between water and EtOAc. The organic layer was separated, washed with brine, dried over anhydrous sodium sulfate, and evaporated under reduced pressure to give the crude product. The crude compound was purified by MPLC using a 24 g Silicycle cartridge and 0-10% methanol in dichloromethane to give a mixture of regioisomers as a pale yellow solid (0.23 g, yield: 51%). The regioisomers were separated by chiral preparative HPLC [LUX CELLULOSE-4, C-18 (250 mm×21.2 mm, 5.0 μm) column; hexane (A) and 0.1% HCOOH:MeOH (1:1) in IPA (B); isocratic elution] to give the title product as an off-white powder (0.15 g, yield: 68%). C-6: ESI-MS m / z: 514.0 [M+H] + (Rt=0.71 min, LC-Method 2); 1 H NMR (300 MHz, CD 3 OD)δ ppm=8.19(s,1H), 7.26(s,2H), 6.51(s,1H), 4.67(t,J=5.7Hz, 2H), 4.14-3.94(m,3H), 2.78-2.72(m,5H), 2.02(s,3H), 1.29(d,J=6.3Hz,3H).

[0295] Example 7: (R)-3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N,2-dimethylpropanamide (Compound C-7) [ka] Step 1: (R)-3-Hydroxy-N,2-dimethylpropanamide To a stirred solution of methyl (R)-3-hydroxy-2-methylpropanoate (0.5 g, 4.24 mmol) in MeOH (5 mL) in a sealed screw-capped tube was added 40% methylamine in methanol (20.5 mL, 114.34 mmol). The contents of the sealed tube were stirred at 85° C. for 20 h. The reaction mixture was evaporated under reduced pressure to give the title product as a yellow solid (0.45 g, 95%). 1 H NMR (400 MHz, chloroform-d3) δ ppm = 5.98 (bs, 1H), 3.72 (m, 2H), 2.82 (d, 3H), 2.47 (m, 1H), 1.172 (d, 3H).

[0296] Step 2: (R)-3-((8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N,2-dimethylpropanamide A solution of 5,8-dichloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-1,6-naphthyridin-4(1H)-one (Intermediate F1, 0.3 g, 0.77 mmol) in acetonitrile (4.00 mL) was diluted with (R)-3-hydroxy-N,2-dimethylpropanamide (0.11 g, 0.92 mmol), K 2 CO 3(0.26 g, 1.91 mmol) and DMAP (0.03 g, 0.23 mmol) were added. The resulting reaction mixture was stirred at 80° C. for 16 h. The reaction mixture was diluted with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure to give the crude product. The crude compound was purified by MPLC using a 12 g Silicycle cartridge and 0-3% MeOH in dichloromethane to give the title product as an off-white solid (0.25 g, yield: 69%). ESI-MS m / z: 471.8 [M+H] + (Rt=1.49 min, LC-Method-6).

[0297] Step 3: (R)-3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N,2-dimethylpropanamide To a stirred solution of (R)-3-((8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N,2-dimethylpropanamide (0.24 g, 0.51 mmol) in DMF (3 mL) was added ethylene glycol (0.09 g, 1.53 mmol) and Cs 2 CO 3 (0.49 g, 1.53 mmol) was added. The reaction mixture was stirred at ambient temperature for 4 h. The reaction mixture was diluted with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure to give the crude product. The crude compound was purified by MPLC using a 12 g Silicycle cartridge and 0-3% MeOH in dichloromethane to give the title product as an off-white solid (0.071 g, yield: 27%). C-7: ESI-MS m / z: 513.9 [M+H] + (Rt=1.39 min, LC-Method-6). ESI-MS m / z:515.90[M+3H] + (Rt=1.39 min, LC-Method-6). 1 H NMR (400 MHz, CD 3OD)δ ppm=8.18(s,1H), 7.26(s,2H), 6.51(s,1H), 4.49-4.45(m,2H), 4.17(t,J=4.8Hz, 2H), 3. 91(t,J=5.2Hz, 2H), 2.83-279(m,1H), 2.77(s,3H), 2.026(s,3H), 1.27(d,J=7.2Hz, 3H).

[0298] Example 8: (S)-3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N,2-dimethylpropanamide (Compound C-8) [ka] Example 8, 0.038 g (off-white solid, yield: 18%), was prepared in a manner similar to Example 7, using (S)-3-hydroxy-2-methylpropanoate instead of (R)-3-hydroxy-2-methylpropanoate. The crude product was purified by preparative HPLC (column: X-select C-18 (19 mm x 250 mm, μm); mobile phase: 0.1% HCOOH in water and acetonitrile; gradient elution). C-8: ESI-MS m / z: 514.2 [M+H] + (Rt=0.78 min, LC-Method-5). 1 H NMR (400MHz, methanol-d4)δ ppm=8.18(s,1H), 7.26(s,2H), 6.51(s,1H), 4.49-4.45(m,2H), 4.18(t,J=4.4Hz, 2H) , 3.91(t,J=5.2Hz, 2H), 2.90(m,1H), 2.77(s,3H), 2.03(s,3H), 1.27(d,J=7.2Hz, 3H).

[0299] Example 9: N-(2-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)ethyl)acetamide (Compound C-9) [ka] Step 1: tert-Butyl (2-((8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)ethyl)carbamate To a stirred solution of 5,8-dichloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-1,6-naphthyridin-4(1H)-one (Intermediate F1, 0.7 g, 1.79 mmol) in acetonitrile (20 mL) was added tert-butyl (2-aminoethyl)carbamate (0.35 g, 2.14 mmol), K 2 CO 3 (0.74 g, 5.36 mmol) and DMAP (0.07 g, 0.54 mmol) were added. The reaction mixture was stirred at 80° C. for 6 h. The reaction mixture was partitioned between water and EtOAc and the aqueous layer was extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure to give the crude product. The crude compound was purified by MPLC using a 12 g Silicycle cartridge and 20-100% ethyl acetate in hexane to give the title product as an off-white solid (0.62 g, yield: 67%). ESI-MS m / z: 516.6 (M+H) + (Rt=1.79 min, LC-Method 4).

[0300] Step 2: 5-(2-aminoethoxy)-8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-1,6-naphthyridin-4(1H)-one hydrochloride To a stirred solution of tert-butyl (2-((8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)ethyl)carbamate (0.6 g, 1.16 mmol) in dioxane (5 mL) was added 4.0 M HCl in 1,4-dioxane (10 mL). The reaction mixture was stirred at 30° C. for 6 h. The volatiles were evaporated under reduced pressure to give the title product as an off-white solid (0.55 g, yield: 100%). The obtained product was used directly in the next step.

[0301] Step 3: N-(2-((8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)ethyl)acetamide To a suspension of 5-(2-aminoethoxy)-8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-1,6-naphthyridin-4(1H)-one hydrochloride (0.54 g, 1.213 mmol) in dichloromethane (10 mL) at 0° C., triethylamine (0.49 mL, 3.64 mmol) and acetyl chloride (0.12 mL, 1.82 mmol) were added. The reaction mixture was stirred at 30° C. for 5 h. The reaction mixture was partitioned between water and EtOAc, and the aqueous layer was extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and evaporated under reduced pressure to give the crude product. The crude product was purified by MPLC using a 24 g Silicycle cartridge and 20-70% ethyl acetate in hexane to give the title product as a yellow semi-solid (0.45 g, yield: 81%). ESI-MS m / z: 458.0 (M+H) + (Rt=1.29 min, LC-Method 5).

[0302] Step 4: N-(2-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)ethyl)acetamide To a stirred solution of N-(2-((8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)ethyl)acetamide (0.2 g, 0.44 mmol) in DMF (5 mL) was added ethylene glycol (0.04 g, 0.65 mmol) and Cs 2 CO 3(0.43 g, 1.31 mmol) was added. The reaction mixture was stirred at 30° C. for 6 h. The organic layer was washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure to give the crude product. The crude product was purified by MPLC using a 24 g Silicycle cartridge and 0-5% methanol in dichloromethane to give the title product as an off-white powder (0.058 g, yield: 32%). C-9: ESI-MS m / z: 499.85 [M+H] + (Rt=1.35 min, LC-Method 6); 1 H NMR (300MHz, methanol-d4) δ ppm=8.18(s,1H), 7.26(s,2H), 6.53(s,1H), 4.55(t,J=5.1Hz, 2H), 4.18(t J=4.2Hz, 2H), 3.92(t J=4.5Hz, 2H), 3.65(t,J=5.4Hz, 2H), 2.03(s,3H), 1.97(s,3H).

[0303] Example 10: (S)-3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxypropoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide (Compound C-10) [ka] To a stirred solution of 3-((8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide [Step 1 of Example 1 (0.450 g, 0.98 mmol)] in DMF (5 mL) was added (S)-propane-1,2-diol (0.11 g, 1.47 mmol) and potassium carbonate (0.19 g, 1.39 mmol). The reaction was stirred at 80° C. for 24 h. The reaction mixture was partitioned between water and EtOAc. The combined organic phase was washed with water, brine and diluted with Na 2 SO 4The crude product was dried over 100 ml of water and evaporated under reduced pressure to give the crude product. The crude product was purified by MPLC (Combi-Flash, 12 g Redisep column and 0-15% MeOH in dichloromethane) and preparative HPLC (column: Kinetex C18 (150 mm x 21.2 mm, 5.0 μm) column; mobile phase: water and acetonitrile; gradient elution) to give the title product as an off-white solid (0.024 g, yield: 10%). C-10: ESI-MS m / z: 514.4 [M+H] + (Rt=0.78 min, LC-Method 5); 1 H NMR (300MHz, chloroform-d3)δ ppm=8.73(s,1H), 8.09(s,1H), 7.02(s,2H), 6.43(s,1H), 5.29(s,1H), 4.57-4.59(m,2H), 4.26-4.36(m,1H), 4.0 1-3.88(m,2H), 2.88(d,J=3.2Hz, 3H), 2.77-2.72(m,2H), 2.29-2.27(m,1H), 1.96(s,3H), 1.34(d,J=4.5Hz, 3H).

[0304] Example 11: 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N,2,2-trimethylpropanamide (Compound C-11) [ka] Step 1: 3-Hydroxy-N,2,2-trimethylpropanamide To a stirred solution of methyl 3-hydroxy-2,2-dimethylpropanoate (0.5 g; 4.23 mmol) in MeOH (12 mL) in a sealed screw-capped tube was added 40% methylamine in methanol (12 mL, 114.28 mmol). The resulting solution was stirred at 85° C. for 12 h. The volatiles were evaporated under high vacuum to give the title product (0.5 g, yield: 100%). 1H NMR (400 MHz, chloroform-d3) δ ppm = 3.70 (s, 2H), 2.80 (t, J = 4.8 Hz, 3H), 1.19 (s, 3H), 1.17 (s, 3H).

[0305] Step 2: 3-((8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N,2,2-trimethylpropanamide To a stirred solution of 5,8-dichloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-1,6-naphthyridin-4(1H)-one (Intermediate F1, 0.25 g; 0.64 mmol) and 3-hydroxy-N,2,2-trimethylpropanamide (0.13 g, 0.96 mmol) in acetonitrile (2.5 mL) was added potassium carbonate (0.22 g, 1.59 mmol) and DMAP (0.02 g, 0.19 mmol). The resulting reaction mixture was stirred at 80° C. for 16 h. The reaction mixture was partitioned between water and EtOAc. The combined organic phase was washed with water, brine and diluted with Na 2 SO 4 The crude product was purified by MPLC (Combi-Flash, 12 g Redisep column and 20-100% ethyl acetate in hexanes) to give the title product as an off-white solid (0.2 g, yield: 64%). ESI-MS m / z: 486.3 [M+H] + (Rt=1.68 min, LC-Method 5).

[0306] Step 3: 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N,2,2-trimethylpropanamide To a solution of 3-((8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N,2,2-trimethylpropanamide (0.2 g, 0.41 mmol) and ethylene glycol (0.1 g, 1.64 mmol) in DMF (3 mL) was added cesium carbonate (0.47 g, 1.44 mmol). The resulting reaction mixture was stirred at room temperature for 5 h. The reaction mixture was partitioned between water and EtOAc. The combined organic phase was washed with water, brine and added with Na 2 SO 4 The crude product was purified by MPLC (Combi-Flash, 12 g Rediff column and 0-3% methanol in dichloromethane) and preparative HPLC (column: YMC-C18 (20 mm x 150 mm, 5.0 μm); mobile phase: 0.02% ammonia in water and acetonitrile, gradient elution) to give the title product as an off-white solid (0.065 g, yield: 34%). C-11: ESI-MS m / z: 528.2 [M+H] + (Rt=1.37 min, LC-Method 5); 1 H NMR (300MHz, methanol-d4)δ ppm=8.19(s,1H), 7.27(s,2H), 6.53(s,1H), 4.33(s,2H), 4.17(s,2H), 3.91(s,2H), 2.79(s,3H), 2.04(s,3H), 1.29(s,6H).

[0307] Example 12: (R)-3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-2-hydroxy-N-methylpropanamide (Compound C-12) [ka] 0.01 g (off-white powder, yield: 10%) of Example 12 was prepared in a manner similar to Example 13, using O-benzyl-D-serine instead of O-benzyl-L-serine. C-12: ESI-MS m / z: 515.9 [M+H] + (Rt=1.36 min, LC-Method-6). 1 H NMR (300MHz, methanol-d4)δ ppm=8.51(bs,1H), 8.19(s,1H), 7.25(s,2H), 6.53(s,1H), 4.64-4.57(m,2H), 4.49(t,J=4.8Hz, 1H), 4.17-4.1 4(t,J=4.4Hz, 2H), 3.90(t,J=4.8Hz, 2H), 2.79(s,3H), 2.02(s,3H). Chiral HPLC (Rt=6.50 min, Chiral HPLC method 1): 99.0%.

[0308] Example 13: (S)-3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-2-hydroxy-N-methylpropanamide (Compound C-13) [ka] Step 1: (S)-3-(benzyloxy)-2-hydroxypropanoic acid 1.0 M H at 0°C 2 SO 4 A solution of O-benzyl-L-serine (10.0 g 51.23 mmol) in 0.5 M NaNO in water (123 mL) was 2 (300 mL; 290.98 mmol) was added dropwise over 1 h at 0° C. The so obtained solution was allowed to warm slowly to ambient temperature over 20 h. The reaction mixture was basified to pH 6-7 with 1.0 M NaOH in water and washed with EtOAc. The aqueous layer was diluted with 1.0 M H 2 SO 4 The mixture was acidified to pH 2 with ethyl acetate and extracted with EtOAc. The combined organic phase was washed with brine and anhydrous Na 2 SO 4Drying over and concentration under reduced pressure gave the product as a pale yellow oil (9.71 g, yield: 97%). 1 H NMR (400MHz, chloroform-d3) δ ppm=7.36-7.26(m,5H), 4.59(dd, 2H, J=2.8Hz, 14.8Hz), 4.38(t,J=3.6Hz, 1H), 3.83-3.76(m,2H).

[0309] Step 2: Methyl (S)-3-(benzyloxy)-2-hydroxypropanoate (S)-3-(benzyloxy)-2-hydroxypropanoic acid (9.7 g, 49.43 mmol) in methanol (50 mL) at 0 °C was added with SOCl over 5 min at 0 °C. 2 (0.72 mL, 9.88 mmol) was added dropwise. The so obtained reaction mixture was stirred at ambient temperature for 1 h. To this reaction mixture was added trimethyl orthoformate (10.81 mL, 98.86 mmol). The resulting reaction mixture was stirred at ambient temperature for 20 h. The volatiles were evaporated under reduced pressure to obtain the crude product. The crude product was purified by Combi-Flash column chromatography using an 80 g Silicycle cartridge and 0-20% EtOAc in hexane to obtain the desired product as a colorless oil (8.58 g Yield: 83%). ESI-MS m / z: 211.10 [M+H] + , (Rt=1.09 min, LC-Method 3). 1 H NMR (400MHz, chloroform-d3)δ ppm=7.36-7.26(m,5H), 4.61(d,1H, J=12.0Hz), 4.53(d,J=12.4Hz, 1H), 4. 34-4.31(m,1H), 3.78(s,3H), 3.75(d,J=3.6Hz, 2H), 3.15(d,J=6.8Hz, 1H).

[0310] Step 3: Methyl (S)-3-(benzyloxy)-2-((tert-butyldimethylsilyl)oxy)propanoate To a stirred solution of methyl (S)-3-(benzyloxy)-2-hydroxypropanoate (8.5 g 40.41 mmol) in dichloromethane (120 mL) at 0° C. was added DMAP (0.99 g; 8.08 mmol), imidazole (3.05 g, 44.85 mmol). The so obtained solution was stirred at 0° C. for 15 min. To this solution was added TBSCl (6.76 g, 44.86 mmol) and stirred at ambient temperature for 44 h. The reaction mixture was diluted with dichloromethane and washed with brine. The organic layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure to obtain the crude product. The crude product was purified by Combi-Flash column chromatography using an 80 g Silicycle cartridge and 0-20% EtOAc in hexane to obtain the desired product as a colorless oil (12.4 g, yield: 95%). 1 H NMR (300MHz, chloroform-d3)δ ppm=7.31-7.26(m,5H), 4.58(d,J=2.1Hz, 2H), 4.41(t,J=6.0Hz, 1H), 3.73(s,3H), 3.66(t,J=3.9Hz, 2H), 0.91(s,9H), 0.10(s,3H), 0.08(s,3H).

[0311] Step 4: Methyl (S)-2-((tert-butyldimethylsilyl)oxy)-3-hydroxypropanoate To a stirred solution of methyl (S)-3-(benzyloxy)-2-((tert-butyldimethylsilyl)oxy)-propanoate (6.0 g, 18.490 mmol) in dichloromethane (20 mL) was added 10% palladium on carbon (0.65 g). The so obtained reaction mixture was stirred under hydrogen atmosphere (1 atm) for 16 h. The reaction mixture was filtered through a pad of Celite and rinsed with dichloromethane. The filtrate was evaporated under reduced pressure to give the crude product. The crude material was purified by Combi-Flash using a 40 g Silicycle cartridge and 0-30% EtOAc in hexane to give the title product as a colorless oil (2.57 g, yield: 59%). 1H NMR (300 MHz, chloroform-d3) δ ppm = 4.29 (t, J = 4.5 Hz, 1H), 3.79 (d, J = 4.5 Hz, 2H), 3.74 (s, 3H), 2.22 (t, J = 6.6 Hz, 1H), 0.90 (s, 9H), 0.13 (s, 3H), 0.08 (s, 3H).

[0312] Step 5: (S)-3-((tert-butyldimethylsilyl)oxy)-2-hydroxy-N-methylpropanamide To a solution of methyl (S)-2-((tert-butyldimethylsilyl)oxy)-3-hydroxypropanoate (2.5 g, 10.66 mmol) in MeOH (5 mL) was added 40% methylamine in methanol (61.5 mL, 160.00 mmol). The resulting reaction mixture was stirred at 85° C. for 12 h. The volatiles were evaporated under high vacuum to give the title product (2.2 g, crude). Note: During amide formation, migration of the silyl group occurred to give the product shown in the title. ESI-MS m / z: 233.75 (M+H) + , (Rt=1.454 min, LC-Method 6). 1 H NMR (300 MHz, chloroform-d3) δ ppm = 4.15 (d, 1H), 4.07 (t, 1H), 3.81-3.65 (m, 1H), 2.94-2.82 (m, 3H), 0.88 (s, 9H), 0.07 (s, 6H).

[0313] Step 6: (S)-3-((tert-butyldimethylsilyl)oxy)-2-((8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide To a solution of 5,8-dichloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-1,6-naphthyridin-4(1H)-one (Intermediate F1, 1.0 g, 2.55 mmol) and (S)-3-((tert-butyldimethylsilyl)oxy)-2-hydroxy-N-methylpropanamide (0.72 g, 3.06 mmol) in acetonitrile (10 mL) was added potassium carbonate (0.88 g, 6.38 mmol), DMAP (0.06 g, 0.51 mmol). The resulting reaction mixture was stirred at 80° C. for 16 h. The reaction mixture was diluted with water and extracted with EtOAC. The combined organic phase was washed with water, brine and diluted with Na 2 SO 4 The crude product was purified by MPLC (Combi-Flash, 40 g Rediff column and 20-100% ethyl acetate in hexanes) to give the title product as a light brown semi-solid (0.52 g, yield: 35%). ESI-MS m / z: 588.05 (M+H). + , (Rt=1.74 min, LC-Method 5). 1 H NMR (300MHz, chloroform-d3)δ ppm=9.13(s,1H), 8.06(s,1H), 7.28(s,2H), 6.43(s,1H), 5.65(t,J=2.7Hz, 1H), 4.25(d ,J=2.7Hz,2H), 2.93(d,J=4.5Hz.3H), 2.04(s,3H), 0.81(s,9H), -0.05(d,J=5.7Hz,6H).

[0314] Step 7: (S)-3-((tert-butyldimethylsilyl)oxy)-2-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide To a solution of (S)-3-((tert-butyldimethylsilyl)oxy)-2-((8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide (0.4 g, 0.68 mmol) and ethylene glycol (0.06 g, 1.02 mmol) in acetonitrile (6 mL) in a screw-cap microwave vial was added cesium carbonate (0.44 g, 1.36 mmol). The resulting reaction mixture was stirred at 80° C. in an Anton Parr microwave reactor for 30 minutes. (Note: This reaction was performed in 4×0.1 g batches). The combined reaction mixture was diluted with water and extracted with EtOAC. The combined organic phase was washed with water, brine and diluted with Na 2 SO 4 The crude product was purified by MPLC using a 24 g Redisep column and 20-100% ethyl acetate in hexane to give the title product as a pale yellow semi-solid (0.15 g, yield: 20%). ESI-MS m / z: 630.2 (M+H). + , (Rt=1.591 min, LC-Method 5). 1 H NMR (400MHz, chloroform-d3)δ ppm=9.21(d,1H), 8.06(s,1H), 7.03(s,2H), 6.43(s,1H), 5.65(t,1H, J=2.1Hz), 4.17(t,2H, J=4Hz), 4.05-4. 02(m,2H), 3.74(s,2H), 2.93(d,3H, J=4.84Hz), 2.10(d,1H, J=6Hz), 1.97(s,3H), 0.81(s,9H), -0.04(m,6H).

[0315] Step 8: (S)-3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-2-hydroxy-N-methylpropanamide To a solution of ((S)-3-((tert-butyldimethylsilyl)oxy)-2-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide (0.15 g, 0.24 mmol) in THF (4 mL) at 0° C. was added 1.0 M TBAF in THF (0.36 mL, 0.36 mmol). The so obtained reaction mixture was stirred at ambient temperature for 1 h. The reaction mixture was quenched with ice-cold water and extracted with EtOAC. The combined organic phase was washed with water, brine and NaCl. 2 SO 4 The crude product was purified by Combi-Flash using a 12 g Redisep silica gel column and 0-1.5% MeOH in dichloromethane and further purified by Combi-Flash using a 12 g Redisep silica gel column and 0-2% MeOH in dichloromethane to give the pure desired product as an off-white solid (0.038 g, yield: 31%). Note: During deprotection of the silyl group, rearrangement of the ether to the title compound occurred. C-13: HRMS m / z: calcd 516.0496 [M+H] + , Actual value 516.0592. ESI-MS m / z:515.9[M+H] + (Rt=1.35 min, LC-Method 6); 1 H NMR (300MHz, methanol-d4)δ ppm=8.19(s,1H), 7.26(s,2H), 6.52(s,1H), 4.63-4.55(m,2H), 4.49-4.47(m,1H), 4.18(t,J=4.2H z, 2H), 3.91(t,J=4.5Hz, 2H), 2.81(s,3H), 2.03(s,3H). Chiral HPLC (Rt=4.80 min, Chiral HPLC method 1): 97.9%.

[0316] Example 14: (S)-3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxy-2-methylpropoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-2-hydroxy-N-methylpropanamide (Compound C-14) [ka] To a solution of (S)-3-((tert-butyldimethylsilyl)oxy)-2-((8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide [Step 6 of Example 13] (0.5 g, 0.85 mmol) and 2-methylpropane-1,2-diol (0.15 g, 1.7 mmol) in DMF (5 mL) was added cesium carbonate (0.83 g, 2.55 mmol). The resulting reaction mixture was stirred at ambient temperature for 2 h. The reaction mixture was diluted with water and extracted with EtOAC. The combined organic phase was washed with water, brine and diluted with Na 2 SO 4 The crude product was purified by Combi-Flash using a 12 g Redisep silica gel column and 0-2% MeOH in dichloromethane and preparative HPLC (Column: ATLANTIS-T3 (250 mm×19 mm, 5.0 μm); Mobile phase: 0.1% HCOOH in water and acetonitrile; Gradient elution) to give the desired product as an off-white solid (0.003 g, Yield: 3%). C-14: ESI-MS m / z: 544.10 [M+H] + (Rt=1.10 min, LC-Method 3); 1 H NMR (300 MHz, methanol-d4) δ ppm = 8.19 (s, 1H), 7.27 (s, 2H), 6.52 (s, 1H), 4.63-4.59 (m, 2H), 4.49-4.47 (m, 1H), 3.91 (s, 2H), 2.81 (s, 3H), 2.03 (s, 3H), 1.33 (s, 6H).Chiral HPLC (Rt = 8.04 min, Chiral HPLC Method 2): 98.6%.

[0317] Example 15: 3-((8-chloro-1-(2,6-dichloro-4-((3-hydroxyoxetan-3-yl)methoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide (Compound C-15) [ka] Step 1: 3-(hydroxymethyl)oxetan-3-ol At 0 °C, THF (1.0 mL) and H 2 A solution of 3-methyleneoxetane (500 mg, 7.13 mmol) in HO (1.0 mL) was diluted with osmium tetroxide (4%) (0.1 mL, 7.13 mmol) and H 2 O 2 (50%) (1.0 mL, 16.32 mmol) was added successively. The mixture was allowed to reach room temperature and stirred for 1 h. It was then diluted with 3 mL of water and filtered through a pad of Celite. The filtrate was concentrated on a rotary evaporator at 42° C. and 50 mbar for 30 min to give the title compound. 1 H NMR (400 MHz, methanol-d4) δ ppm = 4.63-4.48 (m, 4H), 3.70 (s, 2H).

[0318] Step 2: 3-((8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide CH 3 To a solution of 5,8-dichloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-1,6-naphthyridin-4(1H)-one (Intermediate F1, 1500 mg, 3.826 mmol) and 3-hydroxy-N-methylpropanamide (512.9 mg, 4.974 mmol) in CN (50 mL) was added DMAP (233.7 mg, 1.913 mmol) and K 2 CO 3(1586 mg, 11.48 mmol) was added. The mixture was stirred at 80° C. for 16 h. Then it was cooled to room temperature, filtered and washed with MeOH. The filtrate was concentrated to dryness. The residue was purified by flash column 0-10% MeOH / DCM to give the title compound. ESI-MS m / z: 458.1 [M+H] + (Rt=0.93 min, LC-Method 7).

[0319] Step 3: 3-((8-chloro-1-(2,6-dichloro-4-((3-hydroxyoxetan-3-yl)methoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide A solution of 3-((8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide (300 mg, 0.654 mmol) and 3-(hydroxymethyl)oxetan-3-ol (204 mg, 1.96 mmol) in DMF (6 mL) was diluted with Cs 2 CO 3 (1.07 g, 3.27 mmol) was added. The mixture was stirred at 40° C. for 24 h. Then it was cooled to room temperature, diluted in MeOH and filtered. The filtrate was purified by HPLC to give the title compound. C-15: ESI-MS m / z: 541.9 [M+H] + (Rt=0.93 min, LC-Method 7), 1 H NMR (400MHz, methanol-d4)δ ppm=8.20(s,1H), 7.33(s,2H), 6.52(s,1H), 4.71-4.59(m,6H), 4.33(s,2H), 2.79(s,3H), 2.75(t,J=5.9Hz, 2H), 2.04(s,3H).

[0320] Example 16: 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-2,2-difluoro-N-methylpropanamide (Compound C-16) [ka] Step 1: 2,2-Difluoro-3-hydroxy-N-methylpropanamide To a solution of ethyl 2,2-difluoro-3-hydroxypropanoate (0.2 g, 0.65 mmol) in MeOH (1.0 mL) in a sealed screw-cap tube was added 40% methylamine in methanol (2.0 mL). The reaction mixture was stirred at 80° C. for 16 h. The volatiles were evaporated under reduced pressure to give the crude product (0.12 g, yield: 40%). 1 H NMR (300 MHz, methanol-d4D) δ ppm = 6.49 (bs, 1H), 4.06-3.97 (m, 2H), 2.93 (s, 3H).

[0321] Step 2: 3-((8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-2,2-difluoro-N-methylpropanamide A solution of 5,8-dichloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-1,6-naphthyridin-4(1H)-one (Intermediate F1, 0.35 g, 0.88 mmol) and 2,2-difluoro-3-hydroxy-N-methylpropanamide (0.11 g, 0.79 mmol) in acetonitrile (5 mL) was added to the 2 CO 3 (0.3 g, 2.19 mmol) and DMAP (0.03 g, 0.26 mmol) were added. The resulting reaction mixture was stirred at 80° C. for 16 h. The reaction mixture was poured into water and extracted with EtOAc. The combined organic layers were washed with brine and anhydrous Na 2 SO 4 The crude product was purified by MPLC using a 24 g Silicycle column cartridge and 40-70% EtOAc in hexane to give the title product as an off-white solid (0.2 g, yield: 37%). ESI-MS m / z: 493.8 [M+H] +(Rt=1.08 min, LC-Method 6).

[0322] Step 3: 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-2,2-difluoro-N-methylpropanamide In a microwave vial, a solution of 3-((8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-2,2-difluoro-N-methylpropanamide (0.06 g, 0.12 mmol) in DMF (3 mL) was added to the solution. 2 CO 3 (0.04 g, 0.30 mmol) and ethylene glycol (0.01 g, 0.18 mmol) were added. The resulting reaction mixture was stirred at 80° C. in an Anton Parr microwave reactor for 3 h. The reaction mixture was poured into water and extracted with EtOAc. The combined organic layers were washed with brine and anhydrous Na 2 SO 4 The crude product was purified twice by MPLC using a 24 g Redisep cartridge and 5-10% methanol in dichloromethane to give the title product as an off-white solid (0.008 g, yield: 15%). C-16: ESI-MS m / z: 536.05 [M+H] + (Rt=0.83 min, LC-Method-3). 1 H NMR (400MHz, methanol-d4)δ ppm=8.22(s,1H), 7.27(s,2H), 6.52(s,1H), 4.87-4.81(m,2H), 4.18(t,J=4.4Hz, 2H), 3.92(t,J=4.8Hz, 2H), 2.88(s,3H), 2.04(s,3H).

[0323] Example 17: 2-(4-(5-(2-amino-2-oxoethoxy)-8-chloro-2-methyl-4-oxo-1,6-naphthyridin-1(4H)-yl)-3,5-dichlorophenoxy)-N-methylacetamide (Compound C-17) [ka] Step 1: 2-((1-(4-bromo-2,6-dichlorophenyl)-8-chloro-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)acetamide In a sealed screw-cap tube, 1-(4-bromo-2,6-dichlorophenyl)-5,8-dichloro-2-methyl-1,6-naphthyridin-4(1H)-one (Intermediate F2, 5.0 g, 11.06 mmol) in acetonitrile (50 mL), K 2 CO 3 (4.57 g, 33.18 mmol) was added with 2-hydroxyacetamide (0.83 g, 11.06 mmol) and DMAP (0.67 g, 5.53 mmol). The contents of the sealed tube were stirred at 75 °C for 24 h. The reaction mixture was stirred at 5 °C for 24 h. 3 Rinsed with CN. The organic layer was concentrated under reduced pressure. The residue was purified by MPLC using a 40 g Redisep column and 20-100% EtOAc in hexanes to give the title product as an off-white solid (4.5 g, yield: 83%). ESI-MS m / z: 489.85 [M+H] + (Rt=1.48 min, LC-Method 6).

[0324] Step 2: (4-(5-(2-amino-2-oxoethoxy)-8-chloro-2-methyl-4-oxo-1,6-naphthyridin-1(4H)-yl)-3,5-dichlorophenyl)boronic acid In a sealed screw-cap tube, a degassed (with argon) solution of 2-((1-(4-bromo-2,6-dichlorophenyl)-8-chloro-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)acetamide (4.0 g, 8.14 mmol), bis(pinacolato)diboron (3.09 g, 12.21 mmol) and potassium acetate (1.19 g, 12.21 mmol) in 1,4-dioxane (40 mL) was added to the solution of PdCl 2 dppf.DCM (0.66 g, 0.81 mmol) was added. The contents of the sealed tube were stirred at 90° C. for 4 h. The reaction mixture was filtered through a pad of Celite and rinsed with 1,4-dioxane. The filtrate was evaporated under reduced pressure to give the crude product as a light brown solid (4.2 g, crude). The crude product thus obtained was used in the next step without further purification. ESI-MS m / z: 456.0 [M+H] + (Rt=1.38 min, LC-Method 1).

[0325] Step 3: 2-((8-chloro-1-(2,6-dichloro-4-hydroxyphenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)acetamide To a solution of 4-(5-(2-amino-2-oxoethoxy)-8-chloro-2-methyl-4-oxo-1,6-naphthyridin-1(4H)-yl)-3,5-dichlorophenyl)boronic acid (2.5 g, 5.48 mmol) in MeOH:water (20 mL, 1:1) was added Montmorillonite K-10 (2.25 g, 8.22 mmol) and 30% hydrogen peroxide (100 mL). The resulting reaction mixture was stirred at ambient temperature for 4 h. The reaction mixture was quenched with excess ice water and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude product. The crude product was purified by Combi-Flash column chromatography using a 24 g Silicycle cartridge and 20-100 ethyl acetate in hexane to give the title product as an off-white solid (1.3 g, yield: 55%). ESI-MS m / z: 429.9 [M+H] +(Rt=1.41 min, LC-Method 1).

[0326] Step 4: 2-(4-(5-(2-amino-2-oxoethoxy)-8-chloro-2-methyl-4-oxo-1,6-naphthyridin-1(4H)-yl)-3,5-dichlorophenoxy)-N-methylacetamide To a solution of 2-((8-chloro-1-(2,6-dichloro-4-hydroxyphenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)acetamide (0.1 g, 0.23 mmol) in DMF (4 mL) was added potassium carbonate (0.96 g, 0.7 mmol) and 2-bromo-N-methylacetamide (0.05 g, 0.35 mmol). The reaction mixture was stirred at room temperature for 4 h. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude product. The crude product was purified by Combi-Flash column chromatography using a 12 g Redisep column and 70-100% EtOAc in hexane to give the title product as an off-white solid (0.035 g, yield: 38%). C-17: ESI-MS m / z: 499.0 [M+H] + (Rt=1.37 min, LC-Method-1). 1 H NMR (300 MHz, DMSO-d 6 )δ ppm=8.27(s,1H), 8.13(m,2H), 7.60(s,1H), 7.41(s,2H), 6.55(s,1H), 4.74(s,2H), 4.66(s,2H), 2.68(d,J=4.8Hz, 3H), 1.94(s,3H).

[0327] Example 18: 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)propanamide (Compound C-18) [ka] To a solution of 250 mg (0.565 mmol) of 3-((8-chloro-1-(2,6-dichloro-4-hydroxyphenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)propanamide [prepared in a similar manner to step 1-step 3 of Example 17 using 3-hydroxypropanamide instead of 2-hydroxyacetamide] in DMF (5 mL) was added silver carbonate (0.46 g, 1.69 mmol) and 2-bromoethanol (0.14 g, 1.13 mmol). The reaction mixture was stirred at 80° C. for 16 h. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with brine wash, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude product. The crude product was purified by Combi-Flash column chromatography using a 12 g Redisep column and 20-100% EtOAc in hexane followed by preparative HPLC (column: GEMINI 250 mm × 21.2 mm, 5.0 μm); mobile phase: 0.02% NH in water. 4 OH and acetonitrile, gradient elution) to give the title product as an off-white solid (0.022 g, yield: 8%). C-18: ESI-MS m / z: 487.35 [M+1] + (Rt=1.38 min, LC-Method-1). 1 H NMR (300 MHz, DMSO-d 6 )δ ppm=8.23(s,1H), 7.70(s,1H), 7.34(s,2H), 6.94(s,1H), 6.43(s,1H), 4.52(t,J=6.0Hz , 2H), 4.14(t,J=3.9Hz, 2H), 3.74(t,J=4.8Hz, 2H), 2.58(t,J=6.0Hz, 3H), 1.89(s,3H).

[0328] Example 19: N-(3-(8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)propyl)acetamide (Compound C-19) [ka] Step 1: tert-Butyl (3-(8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)propyl)carbamate N 2 (1s,5s)-9-Borabicyclo[3.3.1]nonane (0.5 M in THF) (3.32 mL, 1.66 mmol) was added dropwise to a sealed vial containing tert-butyl allylcarbamate (241 mg, 1.53 mmol) in 3 mL of THF under reduced pressure. The mixture was stirred at room temperature for 16 h. 2 5,8-Dichloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-1,6-naphthyridin-4(1H)-one (Intermediate F1, 500 mg, 1.28 mmol), Pd(Ph) in DMF (10.0 mL) under 3 P) 4 The above solution was added via syringe to a flask charged with 147 mg (128 μmol) and potassium phosphate (2.0 M solution) (1.28 mL, 2.55 mmol). The reaction mixture was rinsed with N for 2 h. 2 The mixture was heated at 80° C. under reduced pressure. Then it was cooled to room temperature, diluted with EtOAc and washed with water. The aqueous layer was extracted with EtOAc. The combined organic layers were concentrated under reduced pressure. The residue was purified by flash column EtOAc / heptane 0-100% to give the title compound. ESI-MS m / z: 514.3 [M+H] + (Rt=1.20 min, LC-Method 7).

[0329] Step 2: 5-(3-aminopropyl)-8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-1,6-naphthyridin-4(1H)-one hydrochloride To a solution of tert-butyl (3-(8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)propyl)carbamate (582 mg, 1.13 mmol) in dioxane (3 mL) was added HCl (4 M in dioxane) (2.83 mL, 11.3 mmol). The mixture was stirred at 23° C. for 2 h. Concentration under reduced pressure and the residue was dried under high vacuum to give the title compound. ESI-MS m / z: 414.2 [M+H] + (Rt=0.77 min, LC-Method 7).

[0330] Step 3: N-(3-(8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)propyl)acetamide To a solution of 5-(3-aminopropyl)-8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-1,6-naphthyridin-4(1H)-one hydrochloride (490 mg, 1.00 mmol) and acetic acid (302 mg, 5.02 mmol) in DMF (10 mL) was added TEA (712 mg, 7.03 mmol) and HATU (497 mg, 1.31 mmol). The mixture was stirred at 23° C. for 1 h. Diluted in MeOH and filtered. The filtrate was purified by HPLC to give the title compound. ESI-MS m / z: 456.2 [M+H] + (Rt=0.91 min, LC-Method 7).

[0331] Step 4: N-(3-(8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)propyl)acetamide A solution of N-(3-(8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)propyl)acetamide (200 mg, 0.44 mmol) and ethane-1,2-diol (81.5 mg, 1.31 mmol) in DMF (6 mL) was diluted with Cs 2 CO 3(428 mg, 1.31 mmol) was added. The mixture was stirred at 23° C. for 16 h. It was diluted in MeOH and filtered. The filtrate was purified by HPLC to give the title compound. C-19: ESI-MS m / z: 498.1 [M+H] + (Rt=0.79 min, LC-Method 7), 1 H NMR (400MHz, methanol-d4)δ ppm=8.49(s,1H), 7.29(s,2H), 6.54(s,1H), 4.26-4.15(m,2H), 3.99-3.87(m,2 H), 3.57-3.44(m,2H), 2.07(s,3H), 1.98(s,3H), 1.97-1.90(m,2H), 2H overlaps with the solvent.

[0332] Example 20: 8-Chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-5-(2-(methylsulfonyl)ethyl)-1,6-naphthyridin-4(1H)-one (Compound C-20) [ka] Step 1: 8-Chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-5-vinyl-1,6-naphthyridin-4(1H)-one To a stirred solution of 5,8-dichloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-1,6-naphthyridin-4(1H)-one (Intermediate F1, 0.4 g, 1.02 mmol) in THF (10 mL) was added tributyl(vinyl)stannane (0.39 g, 1.22 mmol), followed by N 2 The solution was purged with gas. Tri-2-furylphosphine (0.02 g, 0.1 mmol) and Pd 2 (dba) 3 (0.09 g, 0.1 mmol) was added. The reaction mixture was stirred at 70° C. for 16 h. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic phase was washed with brine and added Na 2 SO 4The mixture was dried over 100 ml and the solvent was removed under reduced pressure to give the crude product. The crude product was purified by MPLC (Combi-Flash, 24 g column, gradient elution, 0-40% EtOAc in hexanes) to give the title product as a pale yellow solid (0.21 g, yield: 54%). ESI-MS m / z: 384.40 [M+3H] + (Rt=1.54 min, LC-Method 1).

[0333] Step 2: 8-Chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-5-vinyl-1,6-naphthyridin-4(1H)-one A solution of 8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-5-vinyl-1,6-naphthyridin-4(1H)-one (0.2 g, 0.521 mmol) in DMF (3 mL) was added with ethylene glycol (0.04 g, 0.63 mmol) and K 2 CO 3 (0.22 g, 1.56 mmol) was added. The reaction mixture was stirred at 80° C. for 16 h. The reaction mixture was diluted with water and extracted with EtOAc and EtOAc. The combined organic phase was washed with brine and added Na 2 SO 4 The mixture was dried over 100 ml and the solvent was removed under reduced pressure to give the crude product. The crude product was purified by MPLC (Combi-Flash, 12 g column, gradient elution, 0-10% MeOH in dichloromethane) to give the desired product as a pale yellow solid (0.1 g, yield: 48%). ESI-MS m / z: 424.90 [M+1H] + (Rt=1.45 min, LC-Method 6).

[0334] Step 3: 8-Chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-5-(2-(methylsulfonyl)ethyl)-1,6-naphthyridin-4(1H)-one To a solution of 8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-5-vinyl-1,6-naphthyridin-4(1H)-one (0.08 g, 0.19 mmol) in ethanol (3 mL) was added sodium methanesulfinate (0.19 g, 1.89 mmol) and acetic acid (0.01 g, 0.19 mmol). The reaction mixture was stirred at 60° C. for 16 h. The reaction mixture was concentrated under reduced pressure to give the crude product. The crude product was purified by preparative HPLC (column: X SELECT, 250 mm×19 mm, 5.0 μm), mobile phase: 0.02% NH in water. 4 OH and acetonitrile; gradient elution) to give the title product as an off-white solid (0.04 g, yield: 56%). C-20: ESI-MS m / z: 504.95 [M+1H] + (Rt=1.38 min, LC-Method-6). 1 H NMR (300 MHz, DMSO-d 6 )δ ppm=8.59(s,1H), 7.38(s,2H), 6.59(s,1H), 4.99(t,J=5.4Hz, 1H), 4.17(t,J=4.8Hz , 2H), 3.86-3.82(m,2H), 3.76(m,2H), 3.56-3.51(m,2H), 3.06(s,3H), 1.96(s,3H).

[0335] Example 21: 8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-5-(2-(methylsulfonyl)propyl)-1,6-naphthyridin-4(1H)-one (Compound C-21) [ka] Step 1: 5-Allyl-8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-1,6-naphthyridin-4(1H)-one To a stirred solution of 5,8-dichloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-1,6-naphthyridin-4(1H)-one (Intermediate F1, 0.05 g, 1.28 mmol) in THF (5 mL) was added tributyl(allyl)stannane (0.51 g, 1.53 mmol), followed by N 2 The solution was purged with gas. Tri-2-furylphosphine (0.03 g, 0.13 mmol) and Pd 2 (dba) 3 (0.12 g, 0.13 mmol) was added. The reaction mixture was stirred at 70° C. for 4 h. The reaction mixture was diluted with water and extracted with EtOAc. The organic phase was washed with brine and added Na 2 SO 4 The mixture was dried over 100 ml of ethyl acetate and the solvent was removed under reduced pressure to give the crude product. The crude product was purified by MPLC (Combi-Flash, 12 g column, gradient elution, 20-100% EtOAc in hexanes) to give the desired product as a pale yellow solid (0.27 g, yield: 53.25%). ESI-MS m / z: 397.0 [M+1H] + (Rt=1.77 min, LC-Method 5).

[0336] Step 2: 5-Allyl-8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-1,6-naphthyridin-4(1H)-one A solution of 5-allyl-8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-1,6-naphthyridin-4(1H)-one (0.25 g, 0.63 mmol) in DMF (3 mL) was added with ethylene glycol (0.05 g, 0.75 mmol) and K 2 CO 3 (0.26 g, 1.88 mmol) was added. The reaction mixture was stirred at 80° C. for 16 h. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic phase was washed once with cold water and diluted with Na 2 SO 4The mixture was dried over 100 ml and the solvent was removed under reduced pressure to give the crude product. The crude product was purified by MPLC (Combi-Flash, 12 g column gradient elution, 0-10% MeOH in dichloromethane) to give the desired product as an off-white solid (0.24 g, yield: 87%). ESI-MS m / z: 441.2 [M+3H] + (Rt=0.48 min, LC-Method 4).

[0337] Step 3: 8-Chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-5-(2-(methylsulfonyl)propyl)-1,6-naphthyridin-4(1H)-one To a solution of 5-allyl-8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-1,6-naphthyridin-4(1H)-one (0.23 g, 0.52 mmol) in ethanol (8 mL) was added sodium methanesulfinate (0.53 g, 5.23 mmol) and acetic acid (0.03 g, 0.52 mmol). The reaction mixture was stirred at 60° C. for 16 h. The reaction mixture was concentrated under reduced pressure to give the crude product. The crude product was purified by preparative HPLC (column: Waters xbridge C18, 20 mm×150 mm, 5.0 μm); mobile phase: 0.02% NH in water. 4 C-21: ESI-MS m / z: 519.1 [M+H]. C-22: ESI-MS m / z: 519.1 [M+H]. C-23: ESI-MS m / z: 519.1 [M+H]. C-24: ESI-MS m / z: 519.1 [M+H]. C-25: ESI-MS m / z: 519.1 [M+H]. C-26: ESI-MS m / z: 519.1 [M+H]. C-27: ESI-MS m / z: 519.1 [M+H]. C-28: ESI-MS m / z: 519.1 [M+H]. C-29: ESI-MS m / z: 519.1 [M+H]. C-30: ESI-MS m / z: 519.1 [M+H]. C-31: ESI-MS m / z: 519.1 [M+H]. C-32: ESI-MS m / z: 519.1 [M+H]. C-33: ESI-MS m / z: 519.1 [M+H]. C-34: ESI-MS m / z: 519.1 [M+H]. C-35: ESI-MS m / z: 519.1 [M+H]. C-36: ESI-MS m / z: 519.1 [M+H]. C-37: ESI-MS m / z: 519.1 [M+H]. C-38: ESI-MS m / z: 519.1 [M+H]. C-40: ESI-MS m / z: 519.1 [M+H]. C-41: ESI-MS m / z: 519.1 [M+H]. C-42: ESI-MS m / + (Rt=0.44 min, LC-Method-4). 1H NMR (300MHz, methanol-d4)δ ppm=8.54(s,1H), 7.28(s,2H), 6.55(s,1H), 4.31-4.25(m,1H), 4.19(t,J=4.5Hz, 2H), 3.92(t,J=5 .1Hz, 2H), 3.86-3.82(m,1H), 3.56-3.48(m,1H), 3.08(s,3H), 2.06(s,3H), 1.34(d,J=7.2Hz, 3H).

[0338] Example 22: 8-Chloro-1-(2,6-dichloro-4-(2-hydroxy-2-methylpropoxy)phenyl)-2-methyl-5-(3-(methylsulfonyl)propyl)-1,6-naphthyridin-4(1H)-one (Compound C-22) [ka] Step 1: 8-Chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-5-(3-(methylthio)propyl)-1,6-naphthyridin-4(1H)-one N 2 9-BBN (0.5 M in THF) (3.98 mL, 1.990 mmol) was added dropwise to a sealed vial charged with allyl(methyl)sulfane (0.202 mL, 1.837 mmol) in 3 mL of THF under reduced pressure. The mixture was stirred at room temperature for 16 h. 2 5,8-Dichloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-1,6-naphthyridin-4(1H)-one (Intermediate F1, 600 mg, 1.530 mmol) in DMF (15 mL) under 3 PO 4 (2.0 M) (1.530 mL, 3.06 mmol) and Pd(PPh 3 ) 4 The above solution was added via syringe to a flask charged with 177 mg (0.153 mmol). The reaction mixture was purged with N for 2 h. 2 The mixture was heated to 80° C. under reduced pressure. It was then cooled to room temperature, diluted with EtOAc and washed with water. The aqueous layer was extracted with EtOAc. The combined organic layers were washed with anhydrous Na 2 SO4 The mixture was dried over 100 ml, filtered and concentrated under reduced pressure to give the crude title compound, which was used in the next step without purification. ESI-MS m / z: 445.0 [M+H] + (Rt=1.17 min, LC-Method 7).

[0339] Step 2: 8-Chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-5-(3-(methylsulfonyl)propyl)-1,6-naphthyridin-4(1H)-one H 2 To a solution of oxone (1881 mg, 3.06 mmol) in 2H2O (50 mL) and MeOH (25 mL) was added 8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-5-(3-(methylthio)propyl)-1,6-naphthyridin-4(1H)-one (682 mg, 1.53 mmol) in MeOH (25 mL) dropwise. The mixture was stirred at 23 °C for 4 h. It was then concentrated under reduced pressure to about 50 mL and extracted three times with EtOAc. The combined organic layers were concentrated and purified by flash column 0-100% EtOAc / heptane to give the title compound. ESI-MS m / z: 476.9 [M+H] + (Rt=0.94 min, LC-Method 7).

[0340] Step 3: 8-Chloro-1-(2,6-dichloro-4-(2-hydroxy-2-methylpropoxy)phenyl)-2-methyl-5-(3-(methylsulfonyl)propyl)-1,6-naphthyridin-4(1H)-one A solution of 2-methylpropane-1,2-diol (113 mg, 1.256 mmol) and 8-chloro-1-(2,6-dichloro-4-fluorophenyl)-2-methyl-5-(3-(methylsulfonyl)propyl)-1,6-naphthyridin-4(1H)-one (200 mg, 0.419 mmol) in DMF (4 mL) was diluted with Cs 2 CO 3(409 mg, 1.256 mmol) was added. The reaction mixture was stirred at 50° C. for 16 h. Then it was allowed to cool to room temperature, diluted with MeOH and filtered. The filtrate was purified by HPLC to give the title compound. C-22: ESI-MS m / z: 547.3 [M+H] + (Rt=0.91 min, LC-Method 7), 1 H NMR (400MHz, methanol-d4)δ ppm=8.54(s,1H), 7.30(s,2H), 6.56(s,1H), 3.94(s,2H), 3.65-3.58(m,2H), 3.32-3.24(m,2H), 3.01(s,3H), 2.35-2.22(m,2H), 2.07(s,3H), 1.36(s,6H).

[0341] Example 23: GIRK1 / 4 activity assay The GIRK1 / 4 activity of the compounds according to the present invention was evaluated by the following in vitro method.

[0342] Buffer: a. External buffer: 10 mM NaCl, 50 mM Na gluconate, 80 mM K gluconate, 1.8 mM CaCl 2 , 1 mM MgCl 2 , 10 mM HEPES, 10 mM glucose, pH 7.4; osmolality 300-310 Osm / L. b. Internal buffer: 30 mM KCl, 100 mM K-gluconate, 1 mM MgCl 2 , 10 mM HEPES, 1 mM EGTA, 10 mM NaCl, pH 7.2; osmolality 284-292 Osm / L.

[0343] Compound: c. Prepare a 7-fold compound dilution series (10 mM to 20 uM) in 100% DMSO in a 384-well polypropylene plate. d. Propafenone (Sigma Aldrich, Catalog No. P4670) is used as a positive control and DMSO is used as a neutral control. e. 1 μl of compound in DMSO is resuspended in 66.7 μl of external buffer in a 384-well polypropylene plate and loaded into plate 1 section of a Molecular Devices Quattro®.

[0344] Quattro Settings: f. Load the 384 well Population Patch Plate (Molecular Devices # 9000-0902) into the Quattro. g. Fill the Quattro F-soak bath with 20% DMSO and 50% EtOH. h. Fill the Quattro buffer reservoir with external buffer. i. Attach the inner buffer flask to the Quattro inner buffer tube. j. PBS (phosphate buffered saline, minus Ca ++ and Mg ++ , pH 7.4) bottles are attached to the F-head and E-head washes on the Quattro.

[0345] Antibiotics: k. Resuspend 5.1-5.8 mg of Amphotericin B (Sigma Aldrich, catalog number A2411) in 175 μl of DMSO. l. Add the resulting solution to 50 mL of internal buffer and attach to the antibiotic tubing port on the Quattro.

[0346] cell: m. Use GIRK1 / 4 HEK293 stable cells (obtained from ChanTest, 14656 Neo Parkway, Cleveland, Ohio 44128) grown to approximately 80% confluency in DMEM containing the following cell culture medium: 10% (v / v) fetal bovine serum, penicillin / streptomycin (at "1x" concentration from 100x stock), 0.5 mg / mL G418 and 0.1 mg / mL Zeocin. Cells were detached using Detachin (Genlantis, 11011 Torreyana, San Diego, CA 92121) and resuspended in PBS (minus Ca ++ and Mg ++ ) and washed with external buffer (2.0–2.1 × 10 6 Resuspend in 5 mL of 0.1% CO (500 ng / mL final volume of 5 mL). o. Fill into Quattro cell tank.

[0347] Assay Protocol: The Quattro was controlled using IonWorks v2 software to perform the following steps: p. 3.5 μl of cells plus 3.5 μl of external buffer were added to the wells of a Quattro Patch Plate®. q. Amphotericin B and internal buffer were circulated through the cells. r. The following voltage protocol was applied: Pulse 1: 15 mV for 300 milliseconds (ms), followed by Pulse 2: -120 mV for 400 ms, then Pulse 3: -15 mV for 400 ms and finally Pulse 4: -120 mV to 40 mV for 500 ms (this is the voltage ramp). s. The magnitude of the inward potassium current was measured between 1200 and 1220 ms from the onset of pulse 1 (i.e., during the voltage rise phase). t. 3.5 μl of diluted compound (or DMSO) was added to the wells and steps c-d were repeated (final compound concentrations ranged from 50 uM to 0.1 uM, each concentration was tested in quadruplicate - i.e., 4 separate wells). u. The difference in current magnitude between pre-compound versus post-compound provided a measure of GIRK1 / 4 inhibition.

[0348] Data Analysis: Calculate the IC by plotting the percentage of current inhibition (normalized to DMSO only control) as a function of compound concentration using standard data analysis software. 50 values ​​were calculated.

[0349] Using the above test assays, the compounds of the present invention exhibit inhibitory activity according to Table 5 shown below.

[0350] Example 24: Pharmacokinetic properties The pharmacokinetic properties of the compounds in rats were evaluated by the following in vivo study described below.

[0351] animal Species, strain, and sex: Rat, Sprague-Dawley / CD, male Age / Weight 8-10 weeks / 240-320 grams Animal model Double jugular vein puncture Number of Animals: 3 rats / dose / route for discrete (non-crossover) studies. For crossover studies, n=3 for both IV and PO arms. Housing Environment Animals were housed pre-operatively, three per cage, in polypropylene cages (864 cm2 floor, 18 cm height) containing irradiated corncob bedding with paper shavings. Temperature was maintained at 22±3° C. and relative humidity was maintained between 30% and 70% throughout the study. A 12-hour light and 12-hour dark light cycle was maintained in all rooms using automated timers. Food / Water Animals had free access to food and water throughout the experiment.

[0352] Animal models Rats (250-350 g) were anesthetized at least 4 days before the first drug administration and catheters were surgically implanted in the left and right jugular veins (one for blood sampling and the other for intravenous injection) under sterile conditions. The catheters were exposed and fixed to the neck. Analgesics were administered to the animals pre-surgery for analgesic treatment and then twice at appropriate time points after surgery. Catheterized free-moving animals were individually housed in Macrolon cages and allowed free access to food and water throughout the experiment. After a recovery period of at least 4 days, single test compounds were administered intravenously or orally based on individual body weight.

[0353] Experimental conditions body weight Rats were weighed prior to dose administration and body weights were recorded in the raw data file.

[0354] Formulation Intravenous Test articles were administered as a solution in NMP:PEG 200 (10:90 v / v). Test articles that could not obtain a solution were removed and not used for discrete or cassette administration.

[0355] Oral route Test articles were administered as suspensions in MC:Tween 80:water (0.5:0.1:99.4 w / v / v).

[0356] Dosing regimen Intravenous Test articles were administered to awake rats as solutions and bolus injections or as brief intravenous (IV) injections (30 seconds) via the left jugular catheter. Dose volume was 0.5 mL / kg body weight. Precise start and end times of administration as well as exact dose volume were indicated. Plastic syringes and / or plastic injection tubing were used.

[0357] Oral route The test substances were administered to conscious rats as a solution or suspension into the esophagus via a gavage tube. The dose volume was 5 mL / kg body weight. The exact start time of administration and the exact dose volume were indicated.

[0358] [Table 29]

[0359] Clinical Signs The animals were examined before and after dosing and any clinical signs observed were recorded.

[0360] Sampling collection Blood samples (20 μL) were collected at different time intervals from the right jugular vein catheter of the cannulated animals into tubes containing 10% blood in 2% W / V K2 EDTA (2.0 mg / mL) (if the JV catheter becomes opaque during the PK experiment (i.e. after dosing), blood can exceptionally be collected by tail vein puncture, but this must be specified in the in-life observation and data study report). Blood was collected after intravenous (IV) dosing at 0.083, 0.25, 0.5, 1, 2, 4, 7 and 24 hours after dosing. Blood was collected after oral (PO) dosing: 0.25, 0.5, 1, 2, 4, 7 and 24 hours after dosing.

[0361] It is important that the exact dosing and sampling times are recorded. If and when appropriate, time points may be changed. After the last sampling time, rats were dosed with CO. 2 The animals were euthanized by euthanasia.

[0362] Blood samples were immediately placed on ice, frozen at or below -20°C and stored until analysis. Tubes were placed into plastic bags / storage racks pre-labeled with compound name, sample number, study number, route of administration, time point and date.

[0363] Bioanalysis Formulation Bioanalysis An aliquot of each dosage formulation was sampled, appropriately diluted, and analyzed for drug concentration. The observed concentrations were scaled by the dilution factor to determine the final concentration.

[0364] Blood Sample Bioanalysis The concentrations of compounds in whole blood were quantified using a liquid chromatography / mass spectrometry (LC-MS / MS) assay. 20 μL of each blood sample was precipitated with 100 μL of acetonitrile containing a common internal standard (carbamazepine / telmisartan / verapamil; c=50 ng / mL). Samples were vortexed thoroughly and then centrifuged (5 min, 4° C.). The supernatant (80 μL) was transferred to a clean 96-well plate and mixed with 80 μL of water.

[0365] Samples were injected (1-20 μL) onto a suitable analytical column using various isocratic methods and flow rates. The mobile phase typically consisted of 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B), with additional modifiers as required. Compounds and internal standards were eluted at various retention times. The HPLC system was coupled to a mass spectrometer. MS / MS analysis was typically performed using electrospray ionization (ESI) in positive ionization mode. Compounds and internal standards were monitored using multiple reaction monitoring (MRM).

[0366] Standard curves used for sample quantification spanned several log units. The lower limit of quantification (LLOQ) in blood was determined and used as the cutoff value for analytical sensitivity. Known amounts of compound were added to blood to generate quality control samples with six known concentrations in singlets. The accuracy of the in vivo blood sample concentration determination was considered acceptable if the intra-assay accuracy obtained for the quality control samples was within 70%-130% of the expected concentration. Pharmacokinetic parameters were subsequently calculated from the time-concentration data by noncompartmental regression analysis using an in-house fitting program.

[0367] Pharmacokinetic analysis From the time-concentration data, pharmacokinetic parameters were calculated by noncompartmental regression analysis using an in-house fitting program. AUClast (nM * h) AUClast refers to the area under the concentration versus time curve from t=0 to tlast. This data was calculated from t=0 to Tlast using either the linear trapezoidal method, the log-linear trapezoidal method (where the decay between time points is single exponential), or a combination of both. The choice of method was left to the discretion of the PK analyst (e.g., MAP PTM). CL (mL / min / kg) Clearance, CL was calculated as dose / AUCinf after IV administration. F (%) Extravascular bioavailability, F, is preferably calculated as the dose-normalized ratio of extravascular AUCinf to intravenous AUCinf. As an example, for an orally administered substance: F=[AUCinfPO / PO dose] / [IV AUCinfIV / IV dose]×100%. In studies with a crossover design, F was calculated for each animal.

[0368] In studies without a crossover design and with sequential sampling, the mean intravenous AUCinf was used to calculate the bioavailability for each animal administered by the extravascular route.

[0369] When AUCinf was unavailable (either because λz was not defined or the AUC extrapolation to infinity exceeded 25% of AUCinf), AUClast was used instead of AUCinf in the calculations.

[0370] [Table 30]

[0371] Pharmacokinetic studies of the compound of Example 1 in male beagle dogs administered 0.3 mg / kg IV as a solution and 1 mg / kg PO as a suspension yielded the following PK parameters: Clearance (Cl): 5.5 mL / min / kg; AUC 0-24h : 5270nMh; and Oral bioavailability (F): 87%.

[0372] The low to moderate clearance and good oral bioavailability observed in both rats and dogs for the compounds of formula (I) according to the invention, particularly the compound of Example 1, is consistent with an oral dosing regimen in humans.

[0373] Equivalent Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments specifically described herein which equivalents are intended to be encompassed by the following claims.

Claims

1. Formula (I): 【Chemistry 1】 (In the formula, R 1 is -OH, -C(O)NHR a and a 4- to 6-membered heterocycle optionally substituted with one or more —OH (C 1 ~C 6 ) alkyl; A is -OR 2 Or -SO 2 (C 1 ~C 4 ) alkyl, —NHC(O)R b and -C(O)NHR c (C 1 ~C 6 ) alkyl; R 2 is -NHC(O)R d and -C(O)NHR e (C 1 ~C 6 ) alkyl, and the (C 1 ~C 6 ) the alkyl is further optionally substituted with one or more substituents independently selected from halo, —OH, and —CN; R a , R b , R c , R d and R e are each independently optionally substituted with H and one or more —OH (C 1 ~C 6 ) alkyl; and R 3 (C 1 ~C 4 ) alkyl or a pharma- ceutically acceptable salt thereof.

2. R 1 teeth, 【Chemistry 2】 2. The compound of claim 1, selected from:

3. A is -OR 2 3. The compound of claim 1 or 2, wherein:

4. R e is optionally substituted with H and one or more -OH (C 1 ~C 4 4. The compound according to claim 1, wherein R is an integer from 1 to 3, or a pharma- ceutically acceptable salt thereof.

5. R 2 is -NHC(O)CH 3 , -C(O)NHCH 3 , -C(O)NHCH 2 CH 2 OH and -C(O)NH 2 (C 1 ~C 4 ) alkyl, and the (C 1 ~C 4 5. The compound of claim 1, wherein the alkyl is further optionally substituted with one or more substituents independently selected from halo, -OH and -CN, or a pharma- ceutically acceptable salt thereof.

6. R 2 teeth, 【Chemistry 3】 The compound according to any one of claims 1 to 5, or a pharma- ceutically acceptable salt thereof, selected from:

7. R 3 is -CH 3 7. The compound according to any one of claims 1 to 6, wherein:

8. 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide; 2-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-(2-hydroxyethyl)acetamide; 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxy-2-methylpropoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide; 2-((8-chloro-1-(2,6-dichloro-4-(2-hydroxy-2-methylpropoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylacetamide; 2-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylacetamide; (R)-3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxypropoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide; (R)-3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N,2-dimethylpropanamide; (S)-3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N,2-dimethylpropanamide; N-(2-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)ethyl)acetamide; (S)-3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxypropoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide; 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N,2,2-trimethylpropanamide; (R)-3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-2-hydroxy-N-methylpropanamide; (S)-3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-2-hydroxy-N-methylpropanamide; (S)-3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxy-2-methylpropoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-2-hydroxy-N-methylpropanamide; 3-((8-chloro-1-(2,6-dichloro-4-((3-hydroxyoxetan-3-yl)methoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide; 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-2,2-difluoro-N-methylpropanamide; 2-(4-(5-(2-amino-2-oxoethoxy)-8-chloro-2-methyl-4-oxo-1,6-naphthyridin-1(4H)-yl)-3,5-dichlorophenoxy)-N-methylacetamide; 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)propanamide; N-(3-(8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)propyl)acetamide; 8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-5-(2-(methylsulfonyl)ethyl)-1,6-naphthyridin-4(1H)-one; 8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-5-(2-(methylsulfonyl)propyl)-1,6-naphthyridin-4(1H)-one; and 8-Chloro-1-(2,6-dichloro-4-(2-hydroxy-2-methylpropoxy)phenyl)-2-methyl-5-(3-(methylsulfonyl)propyl)-1,6-naphthyridin-4(1H)-one 2. The compound of claim 1, selected from the group consisting of:

9. 9. The compound according to any one of claims 1 to 8, or a pharma- ceutically acceptable salt thereof, in a crystalline form selected from its free form, a hydrate, a solvate, a polymorph, and a co-crystal.

10. The following crystalline forms: (i) In the free crystalline form designated modification A-1, characterized in that it has an X-ray powder diffraction pattern comprising four or more 2θ values ​​(±0.1°) selected from the 2θ values ​​set out in the following table, when measured at a temperature of about 22° C. using CuKα radiation having a wavelength of 1.5418 Å: 【Table 1】 (ii) In the hydrate crystal form designated modification A-2, characterized in that it has an X-ray powder diffraction pattern comprising four or more 2θ values ​​(±0.1°) selected from the 2θ values ​​set out in the following table, when measured at a temperature of about 22° C. using CuKα radiation having a wavelength of 1.5418 Å: 【Table 2】 (iii) in the hydrate crystal form designated modification A-3, characterized in that it has an X-ray powder diffraction pattern comprising four or more 2θ values ​​(±0.1°) selected from the 2θ values ​​set out in the following table, when measured at a temperature of about 22° C. using CuKα radiation having a wavelength of 1.5418 Å: 【Table 3】 (iv) In the hydrate crystalline form designated modification A-4, characterized in that it has an X-ray powder diffraction pattern comprising four or more 2θ values ​​(±0.1°) selected from the 2θ values ​​set out in the following table, when measured at a temperature of about 22° C. using CuKα radiation having a wavelength of 1.5418 Å: 【Table 4】 (v) In the hydrate crystalline form designated modification A-5, characterized in that it has an X-ray powder diffraction pattern comprising four or more 2θ values ​​(±0.1°) selected from the 2θ values ​​set out in the following table, when measured at a temperature of about 22° C. using CuKα radiation having a wavelength of 1.5418 Å: 【Table 5】 The compound according to claim 9, which is 3-((8-chloro-1-(2,6-dichloro-4-(2-hydroxyethoxy)phenyl)-2-methyl-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)oxy)-N-methylpropanamide in any one of the above.

11. A pharmaceutical composition comprising a compound according to any one of claims 1 to 10, or a pharma- ceutically acceptable salt thereof, and one or more pharma- ceutically acceptable carriers.

12. Class I antiarrhythmics, Class II antiarrhythmics, Class III antiarrhythmics, Class IV antiarrhythmics, Class V antiarrhythmics, cardiac glycosides and other drugs acting on the atrial refractory period; hemostatic regulators, antithrombotic agents; thrombin inhibitors; factor VIla inhibitors; anticoagulants, factor Xa inhibitors and direct thrombin inhibitors; antiplatelet agents, cyclooxygenase inhibitors, adenosine diphosphate (ADP) receptor inhibitors, phosphodiesterase inhibitors, glycoprotein IIB / IIA, adenosine reuptake inhibitors; antidyslipidemic agents, HM G-CoA reductase inhibitors, other cholesterol-lowering agents; bile acid sequestrants; cholesterol absorption inhibitors; cholesteryl ester transfer protein (CETP) inhibitors; inhibitors of the ileal bile acid transport system (IBAT inhibitors); bile acid-binding resins; nicotinic acid and its analogs; antioxidants; omega-3 fatty acids; antihypertensives including adrenergic receptor antagonists, beta-blockers, alpha-blockers, and mixed alpha / beta-blockers; adrenergic receptor agonists, alpha-2 agonists; angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers; angio Tensin II receptor antagonists; aldosterone receptor antagonists; central adrenergic agonists, central alpha agonists; and diuretics; anti-obesity agents, pancreatic lipase inhibitors, microsomal transfer protein (MTP) modulators, diacylglycerol acyltransferase (DGAT) inhibitors, cannabinoid (CBI) receptor antagonists; insulin and insulin analogs; insulin secretagogues; agents that improve incretin action, dipeptidyl peptidase IV (DPP-4) inhibitors, glucagon-like peptide-I (GL P-1) agonists; insulin sensitizers, peroxisome proliferator-activated receptor gamma (PPARγ) agonists, agents that regulate hepatic glucose balance, fructose 1,6-bisphosphatase inhibitors, glycogen phosphorylase inhibitors, glycogen synthase kinase inhibitors, glucokinase activators; agents designed to reduce / delay absorption of glucose from the intestine, α-glucosidase inhibitors; agents that antagonize the action of glucagon or reduce glucagon secretion, amylin analogs;12. The pharmaceutical composition of claim 11, further comprising at least one additional pharma- ceutical active agent selected from an agent that prevents glucose reabsorption by the kidney and a sodium-dependent glucose transporter 2 (SGLT-2) inhibitor.

13. A method for treating or preventing a disease or disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 10 or a pharma- ceutical acceptable salt thereof, or a pharmaceutical composition according to claim 11 or 12.

14. The method of claim 13, wherein the disease or disorder is a disease or disorder that responds to inhibition of the GIRK1 / 4 receptor.

15. The method of claim 13 or 14, wherein the disease or disorder responsive to inhibition of the GIRK1 / 4 receptor is selected from cardiac arrhythmias, atrial fibrillation, bradyarrhythmia, bradycardia, heart block, sick sinus syndrome, parasympathetic hyperresponsiveness, primary aldosteronism, hypotension and vasovagal syncope.

16. A method of maintaining sinus rhythm after cardioversion in a patient with persistent or recent onset atrial fibrillation or preventing recurrence in a patient with paroxysmal atrial fibrillation, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 10 or a pharma- ceutical composition according to claim 11 or 12.

17. The method according to any one of claims 13 to 16, wherein administration of the compound or pharmaceutical composition is oral.

18. A compound according to any one of claims 1 to 10 or a pharma- ceutically acceptable salt thereof or a pharmaceutical composition according to claim 11 or 12 for use as a medicament.

19. The compound according to any one of claims 1 to 10 or a pharma- ceutically acceptable salt thereof, or the pharmaceutical composition according to claim 11 or 12, for use in the treatment of a disease or disorder responsive to inhibition of the GIRK1 / 4 receptor, wherein the disease or disorder responsive to inhibition of the GIRK1 / 4 receptor is selected from cardiac arrhythmia, atrial fibrillation, bradyarrhythmia, bradycardia, heart block, sick sinus syndrome, parasympathetic hyperresponsiveness, primary aldosteronism, hypotension and vasovagal syncope.

20. A compound according to any one of claims 1 to 10 or a pharma- ceutical composition according to claim 11 or 12 for use in maintaining sinus rhythm after cardioversion in patients with persistent or recent onset atrial fibrillation or in preventing recurrence in patients with paroxysmal atrial fibrillation.

21. The compound according to any one of claims 1 to 10 or a pharma- ceutically acceptable salt thereof, or the pharmaceutical composition according to claim 11 or 12, for use in the manufacture of a medicament for treating a disease or disorder responsive to inhibition of the GIRK1 / 4 receptor, wherein the disease or disorder responsive to inhibition of the GIRK1 / 4 receptor is selected from cardiac arrhythmia, atrial fibrillation, bradyarrhythmia, bradycardia, heart block, sick sinus syndrome, parasympathetic hyperresponsiveness, primary aldosteronism, hypotension and vasovagal syncope.

22. Use of a compound according to any one of claims 1 to 10 or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to claim 11 or 12, in the manufacture of a medicament for treating a disease or disorder responsive to inhibition of the GIRK1 / 4 receptor, wherein the disease or disorder responsive to inhibition of the GIRK1 / 4 receptor is selected from cardiac arrhythmia, atrial fibrillation, bradyarrhythmia, bradycardia, heart block, sick sinus syndrome, parasympathetic hyperresponsiveness, primary aldosteronism, hypotension and vasovagal syncope.

23. Use of a compound according to any one of claims 1 to 10 or a pharma- ceutically acceptable salt thereof or a pharmaceutical composition according to claim 11 or 12 in maintaining sinus rhythm after cardioversion in patients with persistent or recent onset atrial fibrillation or in preventing recurrence in patients with paroxysmal atrial fibrillation.

Citation Information

Patent Citations

  • Naphthyridinone derivatives and their use in the treatment of arrhythmia

    WO2018073788A1

  • Selective ligands for modulation of GIRK channels

    WO2019241311A1